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ABSTRACT 
ROBERTO SANDOVAL 
LOWER EXTREMITY SPLINTING TO MANAGE PAIN AND SLEEP 
DISTURBANCES ASSOCIATED WITH HIV/AIDS RELATED  
PERIPHERAL NEUROPATHY 
 
 
MAY 2013 
 
BACKGROUND: Pain, sleep and functional disturbances are a common 
occurrence in people living with HIV/AIDS-related distal symmetrical peripheral 
neuropathy (PLWHA-DSPN), yet lack group classification and quantification. DSPN-
pain is predominantly managed by using systemic agents with little evidence supporting 
their analgesic efficacy. Animal models suggest the presence of analgesic effects 
associated with immobilization. The purpose of this study is to evaluate the effect of 
nighttime lower extremity splinting application on DSPN-related pain and sleep 
disturbances compared to a parallel splint liner application.  
METHODS: Forty-six PLWHA-DSPN were recruited, as part of a two-group 
intervention study, to complete the Neuropathic Pain Scale and The Pittsburgh Sleep 
Quality Index (PSQI) questionnaires. The participant’s performance during a forward 
reach task and walking distance in six minutes was recorded as a measure of function. 
For the intervention study, pain and sleep outcomes were measured at baseline, week 
three and six. The pain outcome was measured using the Neuropathic Pain Scale and the 
sleep outcome using the Pittsburgh Sleep Quality Index.  
	   vii	  
RESULTS: The baseline pain (60.77±17.85) and sleep (14.62±4.28) scores 
denote marked pain and sleep disturbances, compared to seronegative age-matched 
individuals. The ambulation distance was limited (243.99±141.04 m), and inversely 
associated with the PSQI-sleep efficiency subscale (rs=-0.35, p<0.05). The average 
reaching distances measured at baseline (36.07±7.37 cm) were similar to seronegative 
age-matched individuals. Pain, sleep, and functional measures exhibited significant 
associations. Pain and sleep scores improved in both intervention groups over time. The 
median percentage pain reduction at week six was 8% in the liner group and 34% in the 
splint group. The change in pain scores in the splint group was found to be significant 
over time, p<0.0005. The contrast between the splint and liner groups was underpowered 
(26%) and was not found to be significant, p>0.05. Sleep scores improved 20% from 
baseline to the end of the study in both groups; all participants were classified as poor 
sleepers.  
CONCLUSIONS: The data collected suggest that PLWHA-DSPN report 
moderate to severe pain, significant sleep disturbances and limited ambulation distances. 
The six-week use of nighttime splints reduces DSPN-pain. Future studies are needed to 
validate effective non-pharmacological interventions for DSPN 
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CHAPTER I 
 
PROSPECTUS 
INTRODUCTION 
The medical management of people living with the human immunodeficiency 
virus (HIV) that ultimately leads to the development of acquired immunodeficiency 
syndrome (AIDS)1 has progressed dramatically since the beginning of the pandemic 
in the early 1980’s.2,3 Despite advances in management and prevention, an estimated 
33 million people worldwide are infected with this virus.1 Of those, 1.1 million people 
living with HIV/AIDS reside in the United States, while 56,000 new cases are added 
to this total every year.4 Medical providers are challenged to achieve a delicate 
balance between offering effective anti-retroviral medications while monitoring 
undesired side effects in an aging population of people living with HIV/AIDS 
(PLWHA).2,3,5 The life expectancy of PLWHA has continued to increase in the 
industrialized world, approaching parity with non-infected individuals.6 
Pain and sleep disturbances are commonly associated to living with chronic 
systemic diseases such as fibromyalgia, arthritis, chronic liver disease and 
HIV/AIDS.7-9 Data collected from a cohort of 317 PLWHA, indicate that 55% of 
them experienced and ranked increases in pain and sleep disturbances among the top 
four symptoms associated with living with HIV/AIDS. Pain and sleep disturbances 
were only preceded in reported prevalence by self-reported fatigue and drowsiness.10 
A review of systemic diseases’ impact on sleep, suggests that alterations in rapid eye 
movement (REM), non-REM sleep stages, as well as an increase in sleep disturbances 
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are associated with HIV disease progression into AIDS; moreover, 26% of the 
variance in sleep disturbances experienced in that study was attributed to pain and 
other psychosocial factors.11,12 
Distal sensory peripheral neuropathy (DSPN) is among the most common 
complications associated with long-term survival with HIV/AIDS. An estimated 30-
60% of all PLWHA will develop DSPN at some point during the course of the 
disease, with an increased prevalence seen in this patient population as the disease 
progresses from HIV into AIDS.13-15 Functional impairments have also been reported 
in the presence of neuropathies. Different authors16,17 have reported significant 
differences in gait quality, walking speed and total distance walked in individuals 
with damage to the peripheral nervous system. Despite advances in medical 
management of HIV infection, the direct impact of commonly experienced symptoms 
associated with living with HIV/AIDS, such as pain and sleep disturbances in the 
current era of anti-retroviral therapy (ART), has not been extensively reported in the 
literature.  
In a recent pilot study,18 the use of night time lower extremity (LE) splinting 
showed promising results in the management of pain and sleep disturbances. This 
pilot study design was a crossover study that included 22 PLWHA and DSPN and 
evaluated the effects of a three-week bilateral LE splints application on pain and 
sleep. A 20% improvement in both pain and sleep scores was reported in this pilot 
study. Additionally, a moderate effect size for pain and sleep scores was found. The 
results suggest that the analgesic effect of the splint application persisted for a period 
of several weeks following discontinuation of the splint application. These results 
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were obtained using a relatively small sample of patients and without long-term 
follow-up post-splinting application. Finally, that study could not determine whether 
the source of the pain inhibition was due to the application of a full contact protective 
sheath on the lower leg or the short-term immobilization at the ankle joints provided 
by the splints.  
Purpose and Hypotheses 
The purpose and primary aim of this study was to evaluate the impact on pain 
and sleep disturbances in PLWHA-related DSPN attributed to the use of bilateral LE 
splints versus a control intervention of bilateral LE splint liner application. The null 
hypotheses for the primary aim were that: 1) there is no difference in pain and sleep 
scores between the bilateral LE splints and those obtained using the splint liners only 
following a three and six-week application, 2) there is no difference in pain and sleep 
scores between baseline and following a six-week LE splint application. The 
secondary aim was to identify factors influencing function, as measured by the 
functional reach (FR) test and the six-minute walk distance (6MWD), and their 
relationship with pain and sleep disturbances in the presence of HIV/AIDS-related 
neuropathy.  
METHODS 
Participants 
Adult ambulatory PLWHA and a clinical diagnosis of DSPN were recruited to 
participate in this prospective randomized clinical trial from the Thomas Street Clinic 
Health Center, Harris Health System, Houston, Texas. Based on data from completed 
pilot work, an a priori power analysis was completed assuming equal distribution of 
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means, standard deviations and a moderate effect size (η2=0.46) of the bilateral LE 
splint application in both groups for self-reported pain scores. Based on these 
assumptions, a minimum of 24 participants per group would be necessary to achieve a 
statistical power of 0.80 for a repeated measure between factor analysis. Originally, 
enrolling up to 88 PLWHA and DSPN was the projected number of participants 
needed to reach or slightly exceed the expected statistical power of 0.80, assuming an 
attrition rate of 50%. Participant recruitment difficulties precluded meeting the 
number of projected participants, impacting the between intervention planned 
contrasts of interest. 
Inclusion and Exclusion Criteria  
Adult PLWHA 18 and older, with a clinical diagnosis of symptomatic bilateral 
LE DSPN were invited to participate. The participants were on a stable pain and 
HIV/AIDS management regimen without foreseeable alterations or changes to said 
pharmacological regimen, which included pain medications, sleep medications or 
both. The participants were community dwelling individuals, able to walk at or above 
a modified independence level with or without the need of an assistive device, such as 
a cane or walker to ambulate. Eligible participants reported at least one of the 
following clinical symptoms: paresthesia, dysesthesia, or night cramps in the LE. 
Participants were excluded if they had a clinical diagnosis of any of the following: 
significant cardiovascular or pulmonary disease (specifically, myocardial infarction 
within the past six months, angina, or dyspnea at rest), paraplegia, hemiplegia, other 
major neurological dysfunction, diabetes, absent pedal pulse during examination, 
sleep apnea, or pregnancy. Additionally, patients unable to read English, with changes 
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to their pharmacological management during the study, or using any mechanical 
devices to assist in normalizing sleep were excluded from this study.  
Instrumentation 
Splinting intervention. Walkabout™ splints (Don Joy Orthopedics, Vista, 
CA, USA) were used in the splinting treatment. The Walkabout splint is a one-piece 
injection molded walking boot fitted with a rocker bottom allowing for ambulation. 
The participants were fitted and instructed to wear the bilateral LE splints to sleep for 
the duration of the study. 
Control intervention. The liner or protective sheath from the Walkabout™ 
splint were applied to the LEs, with the structural frame of the splint removed by the 
researcher in advance. Patients were blinded to this arm of the study. 
Pain measure. A composite pain score were collected using the self-reported 
Neuropathic Pain Scale (NPS). In this 0 to 100 scale, the patient was asked to quantify 
the different aspects of the pain experience in the presence of neuropathies. Galer and 
Jensen19 reported that the NPS exhibits both predictive and discriminate validity as 
well as being sensitive to the effect of treatments impacting neuropathic pain. The 
aggregate NPS score obtained using the NPS were computed and used in the data 
analysis. 
Sleep quality and quantity. The Pittsburgh Sleep Quality Index (PSQI) is a 
ten item questionnaire, covering the following seven components of sleep: subjective 
sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, use of sleeping medications, and daytime dysfunctions. Buysse et al.20 
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reported sensitivity and specificity values of 89.6% and 86.5%, respectively, for this 
scale in identifying good and poor sleepers. 
Functional tests. Simmonds et al.21 reported approximately a 30% decrease in 
total distance walked in a six-minute period, 421.44±83.56 meters (m) for participants 
with HIV/AIDS participants as compared to 608.15±108.74 m for normal age-
matched counterparts. More importantly, the authors associated 26% of the variance 
in self-reported quality of life to the combined influence of self-reported pain, the 
6MWD, and the FR. The 6MWD and the FR test were collected using the same 
methods used by Simmonds et al.21 Both the 6MWD and FR test in this study 
exhibited inter-session Intra-Class Correlation Coefficient (ICC) value >0.83.22 The 
participants were instructed to perform these tasks within their respective functional 
abilities; additionally, the researcher monitored the participants’ mobility for safety 
considerations during all data collection sessions. 
Forward reach (FR) test. For this test, the investigators asked the participants 
to stand next to a wall without shoes and with their feet positioned hip-width apart on 
the floor with one shoulder close to the wall. The baseline measurement was taken by 
asking the participant to lift both arms to shoulder level and a wall-affixed yardstick 
was adjusted to the height of the acromion closest to the wall. The starting point, for 
each reaching attempt, was identified along the yardstick by locating the bony 
landmark of the distal aspect of the ulna (styloid process) on the arm that was closest 
to the wall. The participant was then asked to lower the arm farthest away from the 
wall and was instructed “to reach as far forward as possible, without losing your 
balance, touching the wall or stepping and crossing the tile threshold on the floor.” 
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Participants using assistive devices to ambulate were instructed not to use their 
respective walking aid, but to also follow the same reaching instructions. The average 
distance of three reaching attempts was recorded and used in the analysis.  
Six-minute walk distance (6MWD). For this test the participants were 
instructed to: “Please walk as far, as fast and as safe as you can for up to six minutes”. 
The walking test was performed in a climate-controlled environment, on a level 
surface void of obstacles and with a pre-determined path of 20 m per lap. The 
beginning and end of the 10 m path was clearly marked with taped trapezoids to the 
non-skid floor. The numbers of laps covered in six minutes was recorded. The partial 
laps were counted in feet by counting each additional floor tile (measuring 
approximately 30 cm in length) walked and the total distance walked in six minutes 
was calculated and used in the analysis. 
Procedures  
All participants who qualified and agreed to participate signed a consent form 
approved by the institutional review boards of HHS and Texas Woman’s University. 
Baseline demographics, HIV disease markers and medications were collected to 
describe the participants in this study. The participants self-selected the order of 
completion and complete the NPS and the PSQI questionnaires. The questionnaires 
were followed by the 6MWD and FR test. The functional tests were performed in 
random order. The primary assessor of the study collected both self-report and 
functional measures. The same assessor performed all subsequent data collection. 
After baseline assessment, the participants were randomly assigned, using a pre-coded 
table, to either the LE splint application or splint liner only application group. Thus, 
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the participants and the researcher were blinded to the participants’ group allocation at 
baseline assessment.  
The researcher individually fitted each participant with either bilateral 
WalkaboutTM splints or bilateral WalkaboutTM splint liners according to their group 
assignment. The researcher provided instruction regarding LE splint or LE liner 
application to each participant based on their respective treatment group assignment. 
Both groups received the same instruction to wear their devices at night while 
sleeping.  
The participants were asked to return to the clinic at weeks three and six to 
complete the NPS, PSQI and the functional tasks. The functional measures were 
collected in the same random manner as in the initial data collection session. All 
participants were contacted weekly by telephone to record compliance and to 
document issues concerning muscle soreness or other reasons interfering with the 
wearing of the splints or splint liners. As an incentive for participation in this study, 
the participants received a $20 grocery gift card at each follow-up session (week three 
and week six) or a total of $40 in grocery vouchers. 
Data Analysis 
The data analysis was performed using SPSS version 16.0 (SPSS Inc., 
Chicago, Il, USA). Descriptive statistics including measurement of central tendency 
such as means, modes, minimum scores, and maximum scores were computed on all 
variables. 
Aim number one was tested using two separate repeated measures Analyses of 
variances (ANOVA), for the dependent variables NPS and PSQI. The level of 
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significance was split at p<0.04 for the pain score analysis and p<0.01 for the sleep 
scores as the pain scale is more comprehensive, specific, and more importantly, the 
scores are sensitive to changes in the symptoms experienced in the presence of 
DSPN.19 Furthermore, the PSQI was designed to categorize individuals into “good” 
and “poor sleepers,” thus small changes in this ordinal level of measure scale may be 
difficult to interpret as clinically relevant.7,20,23 The alpha allocation of 80% into the 
pain scores and 20% sleep index scores, in turn, optimized the statistical power for the 
factor “pain scores” in this study. The 3X2 ANOVA for the dependent variable, NPS, 
were calculated, with time (three levels) and group (two levels). A Kruskal-Wallis 
ANOVA was used for the non-parametric sleep quality score obtained with the PSQI, 
again with time (three levels) and group (two levels). Each ANOVA was followed by 
two planned contrasts of interest: two between group contrasts and a single additional 
within group contrast of interest in the splint group. The within group contrast 
evaluated the difference in pain scores between the initial visit and week six in the 
splint group. The difference between pain and sleep scores at week three and six 
between the splint group versus the liner only group was evaluated using four separate 
between intervention contrasts. Thus, each pain score contrast of interest was tested 
using an adjusted alpha level of 0.013 (or 0.04/3), while the sleep scores contrasts 
were tested at an adjusted alpha level of 0.005 (or 0.01/2).  
Aim number two was evaluated by using a correlation matrix utilizing 
correlation coefficients to illustrate the strength of relationships between the pain 
scores, sleep scores and functional measures with an alpha level set at 0.05. A 
multiple dependent variable analysis of variance (MANOVA) with post-hoc analysis 
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was originally planned to evaluate the strength and statistical significance of the 
variance in pain scores associated with the 6MWD and distances reached. Participant 
recruitment difficulties precluded meeting the number of projected participants; 
therefore, the between factor MANOVA analysis was not performed. 
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CHAPTER II 
 
REVIEW OF THE LITERATURE 
INTRODUCTION 
The medical management of people living with the Human Immunodeficiency 
Virus (HIV) that ultimately leads to the development of Acquired Immunodeficiency 
Syndrome (AIDS) has progressed dramatically since the beginning of the pandemic in 
the1980’s.1-3 Despite advances in management and prevention, an estimated 33 
million people worldwide are infected with this virus.1 Of those, 1.1 million People 
Living With HIV/AIDS (PLWHA) reside in the United States, while 56,000 new 
cases are added to this total every year.4 In America, 20% of all the PLWHA are 
unaware of their seropositive status, and due to the insidious nature of HIV infection, 
many in this population seek medical attention months or years following the initial 
exposure to HIV.4 Medical providers are challenged to achieve a delicate balance 
between offering effective antiretroviral therapy (ART) while monitoring undesired 
side effects in an aging population of PLWHA.2,3,5 The life expectancy of PLWHA 
has continued to increase in the industrialized nations, approaching parity with non-
infected individuals.6 
Pain and sleep disturbances are commonly associated with chronic systemic 
diseases such as fibromyalgia, arthritis, chronic liver disease, and HIV/AIDS.7-9 Data 
collected from a cohort of 317 PLWHA indicate that more than half of them 
experienced and ranked increases in pain and sleep disturbances among the top four 
symptoms associated with living with HIV/AIDS.10-13 Pain and sleep disturbances 
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were only preceded in reported prevalence by self-reported fatigue and drowsiness.10 
A review of systemic diseases’ impact on sleep suggests that alterations in rapid eye 
movement (REM), non-REM sleep stages, as well as an increase in sleep disturbances 
are associated with HIV disease progression into AIDS.14 Moreover, 26% of the 
variance in sleep disturbances experienced by PLWHA in that study was attributed to 
pain and other psychosocial factors.13,15 The purposes of this chapter are to: 1) provide 
an overview of pain pathways, pathophysiology and diagnosis of HIV/AIDS-related 
neuropathy, neuropathic pain treatment management guidelines, pharmacological 
treatment options, non-pharmacological treatment options, impact of HIV-related 
neuropathies on sleep and function and 2) review the psychometric properties of 
instruments used to measure pain, sleep and function.  
PHYSIOLOGY AND PATHOPHYSIOLOGY 
Normal Pain Pathway 
A growing body of evidence is available describing the pain pathways from 
peripheral sensors to central integration.16-25 External physical or chemical noxious 
stimuli are perceived by skin receptors, such as mechanoreceptors and free nerve 
endings, which are imbedded at multiple depths within the dermis and epidermis.20,26 
The skin sensor’s role is to translate external stimuli into action potentials for 
processing within the neuraxis. The sodium potassium pump, located within the 
cellular membrane, actively transfers ions, which are involved in the depolarization of 
nerve cells.25,27 Ions are transferred from a relative low intracellular sodium ion 
concentration environment to a high concentration outside the cell.25,27 The ion 
transfer against molarity is achieved by binding adenosine triphosphate (ATP) 
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produced by mitochondria, to the ion transfer pump.25,27 The energy released by the 
binding of ATP opens the sodium potassium channel to allow for the ion 
exchanges.25,27 Sodium ions are released, and potassium ions enter the cell in 
exchange.25,27 The net results in a voltage differential in the cell creating an action 
potential that may now be transported within the axon.25,27,28  
The density of nerve fibers in the skin varies greatly depending on the area of 
the body. An increased concentration of nerve fibers is found in sensitive areas of the 
human body, such as the hands and face. A smaller density of nerve fibers is found in 
large surface areas such as the trunk and thighs. Thus, “two-point” sensory 
discrimination has a much smaller distance on the tip of the index finger than at the 
thorax.28,29  
Nociceptive stimuli originating at the periphery can travel simultaneously 
along multiple nerve fibers, such as large myelinated fibers (Aα afferent fibers) and 
small unmyelinated fibers (α/δ fibers).25 Schwann cells are responsible for the 
production of myelin, insulating the nerve and ensuring a more efficient transfer of 
action potentials.20,25 The speed of stimuli transmission and integration depends 
greatly on the pathway travelled, with large myelinated 1A fibers exhibiting 
considerably faster conduction speeds compared to smaller α/δ fibers. The speed of 
signal transmission is accepted to be proportionate to the size and presence of the 
myelin sheath insulating the nerve.14,20,25 The conduction speed of large afferent fibers 
has been reported to be as much as 100 times faster than unmyelinated fibers, while 
their diameter can be 15 times larger than unmyelinated fibers.14,20 Motor and 
autonomic fibers are bundled together with large sensory afferent fibers to constitute 
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peripheral nerves.25  
The afferent sensory fibers enter the spinal cord after relaying the message at 
the dorsal root ganglia (DRG) in the dorsal horns.25,30 The DRG contain the cell body 
of the afferent neurons, and the DRG extend axons synapsing with afferent neuron 
pools in the spinal cord.20 Some of the axons from the DRG also synapse with 
interneuronal pools within the spinal cord.22,25 These interneuronal pools maintain a 
complex web of inhibitory and excitatory synapses with afferent and efferent neurons. 
The synaptic connectivity of these interneurons spans multiple spinal segments 
maintaining ipsilateral and contralateral connections to efferent motor neuron pools.25 
In the presence of strong excitatory nociceptive stimulation, these clusters of motor 
neurons activate postural and prime mover muscles to withdraw the extremity or 
segment being subjected to actual or potential tissue damage.25,30 The nociceptive 
signal at the spinal level is modulated by action potentials triggering the release of 
excitatory (glutamate, aspartate) or inhibitory γ-aminobutyric acid (GABA) 
neurotransmitters.24,31-33  
The nociceptive signal proceeds to higher integration centers contralateral to 
the nociceptive stimulus using the spinothalamic tract.25,30 The signal is initially 
processed at the thalamus before synapsing with the limbic system for final signal 
integration and memory storage within the central nervous system.25,30 A delicate 
balance of inhibition and excitation is paramount for nociceptive signal transmission, 
processing, and integration along the neuraxis.24,25,31 Disruptions to the balance 
between excitatory and inhibitory stimuli can have detrimental impacts on the quality 
of peripheral sensory stimuli integration and the associated motor and autonomic 
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responses along the neuraxis. Conversely, the inherent complexity of the pain 
pathway offers multiple analgesic avenues to accomplish optimal pain management in 
individuals presenting with complex pain syndromes.16,17 In summary, the normal 
pain pathway requires the coordination of complex events along the neuraxis. The 
normal response to a noxious stimulus would trigger events at the dermis, spinal cord, 
and central structures resulting in responses that should be proportionate to the actual 
or potential tissue damage.  
Distal Sensory Peripheral Neuropathy (DSPN)  
Distal sensory peripheral neuropathy (DSPN) is among the most common 
complications associated with long-term survival in PLWHA. An estimated 30-60% 
of all PLWHA will develop DSPN at some point during the course of the disease, 
with an increased prevalence seen in this patient population as the disease progresses 
from HIV into AIDS.34-36 Evans et al.37 reported symptomatic DSPN in 32% of the 
2141 patients in their AIDS Clinical Trial Group (ACTG); all of these patients were 
using modern ART regimens.37 The authors computed odds ratios (OR) to quantify 
the risk of developing symptomatic DSPN. The following statistically significant ORs 
were reported to be associated with developing symptomatic DSPN: “age of the 
participant” OR=1.83 (95% confidence interval [CI]=1.60-2.09, p<0.001), “current 
cluster of differentiation type 4 (CD4) cell counts of 200 or less” compared to “CD4 
count of 501 or greater” OR=1.75 (95% CI=1.25-2.46, p=0.011), “higher viremia at 
baseline” OR=1.23 (95% CI=1.02-1.48, p=0.03), “current use of ART including 
nucleoside reverse transcriptase tnhibitor (NRTI)” OR=1.60 (95% CI=1.28-2.00, 
p<0.001), “history of diabetes” OR=3.15 (95% CI=1.74-5.70, p=0.001), “taller 
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height” OR=1.11(95% CI=1.02-1.21, p=0.014), “use of statin medication” OR=1.45 
(95% CI=1.15-1.82, p=0.004), and “fewer years since starting ART medication” 
OR=0.95 (95% CI=0.91-0.99, p=0.046). Conversely, “viral suppression” and 
“baseline CD4 cell count” were not associated with a statistically significant OR for 
developing symptomatic DSPN.37 A clinical profile associated with the highest odds 
of developing DSPN has thus emerged: a PLWHA who has a history of diabetes, is 
older, has CD4 cell counts <200 cells/mm3, follows a NRTI-based ART, is using 
statins to regulate lipids, exhibits high viral load counts at baseline HIV diagnosis, is 
tall, and has recently began ART.  
The pathophysiology of DSPN is multifactorial but directly associated with 
continued HIV replication, unintended side effects associated with viral suppression 
agents, and finally, a synergistic contribution of the aforementioned factors.38,39 
Evidence collected using human and animal models have elucidated HIV infection 
contribution to the development of DSPN via direct and indirect pathways.34,38-49 
Chemokine (C-X-C motif) receptors type 4 (CCRX4) and chemokine (C-C motif) 
receptors type 5 (CCR5), which are expressed on the surface of many cells, including 
neurons and Schwann cells, are used as co-receptors with CD4 to allow HIV entrance 
to host cells.38,45 CD4 is a glycoprotein found on the surface of thymus-helper cells 
(“T-cells” or “CD4 cells”) and macrophages but is not expressed on the surface of 
neurons or Schwann cells.38,50 The cellular binding of glycoprotein 120 (Gp-120), a 
crucial protein exposed in the surface of the HIV virion and which action is to seek 
out entry into host’s cells, initiates a chain of direct inflammatory reactions mediated 
by macrophages.38,45 Macrophages that have been infiltrated with HIV begin 
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production of neurotoxic chemokines such as Interleukin 1-beta (IL-β) and tumor 
necrosis factor-alpha (TNF-α), essential proproteins mediating an inflammatory 
response within the DRG neurons.38,45,51,52 The presence of these chemokines 
activates caspase protease pathways (also known as “executioner proteins” because of 
their essential role in cell death) leading to axonal degeneration and cell death by 
interfering with essential mitochondrial function.45,53,54 Indirectly, DRG Schwann 
cells, upon binding with Gp-120, begin production of chemokine (C-C motif) Ligand 
5 (CCL5), also known as “regulated upon activation, normal T-cell expressed, and 
secreted” proteins or RANTES.45,53,54 RANTES bind with CCR5 receptors present in 
the cell wall of DRG neurons triggering intrinsic production of TNF-α. This 
compounds the inflammatory effect of exogenous inflammatory agents originating 
from HIV-infiltrated macrophages. This synergistic action contributes to apoptosis of 
DRG neurons.45,55  
Kaul et al.50 confirmed the physiological contribution to neuronal cell damage 
initiated by the binding of Gp-120 with CXCR4 and CCR5 co-receptors. The authors 
exposed cerebro-cortical cultures to HIV Gp-120 in vitro to assess the ensuing 
chemokine-mediated reaction. The cerebro-cortical cultures were obtained from mice 
that exhibited the following tropic expressions: expressed CXCR4 only, expressed 
CCR5 only, expressed neither CCR5 nor CXCR4, or exhibited a mixed 
CCR5/CXCR4 expression. The HIV-1 strains used included “wild type” as well as 
tropism variations of CXCR4, CCR5 and mixed tropism virions. The authors 
concluded that the damage observed in neurons in their cultures was associated with 
indirect Gp-120 mediated neurotoxic events, responsible for the inflammatory 
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response and subsequent neuron cell death or apoptosis. The indirect neurotoxin 
production of the inflammatory mediating agents was attributed to HIV- infiltrated 
macrophages production of neurotoxic chemokines (CCL5, IL-β), leading to neuronal 
damage and ultimately apoptosis of neurons in their cell cultures.52,56 Kaul et al.50 also 
identified a neuroprotective mechanism associated with the presence of CCR5 
independent of HIV tropism exposure by partially modulating CXCR4-mediated 
toxicity through heterologous desensitization.50  
Outside the DRG, Gp-120 binds with CXCR4 and CCR5 co-receptors located 
along the peripheral axon directly affecting mitochondrial function and initiating 
caspase activation, resulting in distal loss of nerve fiber densities and axonal 
retraction.57,58 The caspase pathway activation alters the sodium potassium pump’s 
function by releasing potassium ions from the damaged axon. This process has been 
associated with macrophage-mediated phagocytosis in chronic inflammatory disease 
processes, such as crushed nerve injuries and multiple sclerosis.27,59  
The changes observed at the periphery, namely the moderate to severe loss of 
nerve fiber density, are associated with mechanical and thermal hypernociception.57,58 
Hermann et al.57 reported decreased nerve fiber densities based on punch biopsies 
collected 10 cm proximal to the lateral malleoli in patients with DSPN. The 57 
participants in their study were divided into 4 groups: a seronegative HIV age 
matched control group, a group of PLWHA participants not diagnosed with DSPN, a 
group of PLWAH participants with asymptomatic HIV-related DSPN and a group of 
PLWHA participants with asymptomatic HIV-related DSPN. The PLWHA 
participants in this study were predominantly males in their forties, had been living 
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with HIV diagnosis on average for eight years, were on ART and exhibited active 
viremia with log plasma viral loads ranging from 3.4 to 3.9. The authors reported 
significantly less nerve fiber densities in their biopsy samples between the 
seronegative HIV controls (16.6±5.3 fibers/mm), PLWHA participants with 
asymptomatic HIV-related DSPN (9.7±4.2 fibers/mm, p<0.003), and PLWHA and 
symptomatic HIV-related DSPN (8.7±4.0 fibers/mm, p<0.001). The group of 
PLWHA not diagnosed with DSPN also exhibited decrease in fiber density (11.7±6.4 
fibers/mm) but this difference was not statistically significant based on the number of 
statistical contrasts performed. The authors’ findings support the hypothesis of 
neurotoxicity associated to HIV virus activity, namely Gp-120 exposure to neurites. 
Paradoxically, axonal Schwann cells appear to provide an additional physical 
protective barrier to Gp-120 exposure, as similar rat neuron cultures devoid of axonal 
Schwann cells exhibited more neurite retraction and distal degeneration mediated by 
caspase pathways than neuron cultures with Schwann cells.53  
Hypernociceptive activity has been attributed to binding of Gp-120 to axons 
outside of the DRG using chemokines receptors inducing a depolarization of the 
axonal cell membrane.32 This depolarization, in turn, triggers production of 
neuropeptides such as substance P, commonly associated with inflammatory 
processes and pain. Sensitization of the transient receptor potential cation channel 
subfamily V, member 1 (TRPV1), which normal function is to assist in the 
temperature regulation and the sensitization of bradykinin receptors, is commonly 
associated with both chronic and acute inflammatory conditions.38,45,51,52 Another 
mechanism that may also play a significant role in hypernociception is the HIV-
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infiltrated macrophages production of TNF-α within the peripheral axon leading to 
neurite retraction.38,45,51,52 The result of these chemokine events has been associated 
with astrogliosis or neuronal scarring at the corresponding spinal segment.38,45,51,52 
Astrocyte swelling, which precedes astrogliosis, results in an increase of glutamate 
neurotransmitter release in the spinal segment.60 The increased concentration of 
glutamate results in an excitatory environment by offsetting the balance between 
excitatory and inhibitory neurotransmitters at the spinal segment, where reverberating 
action potentials may loop and amplify innocuous peripheral sensation at local and 
higher levels of pain integration.33,52,61 The clinical presentation of allodynia in 
symptomatic cases of DSPN may be associated with the loss of peripheral nerve fiber 
densities resulting in neurite retraction. Thus, continuous exposure to Gp-120 is 
associated with inflammatory processes leading to hypernociception via sensitization 
of peripheral and central pain pathways.38,45,51,52 
Napadow et al.62 recently evaluated changes to the somatosensory cortex of 
patients with chronic carpal tunnel syndrome (CTS), the most common clinical 
presentation of peripheral neuropathy, using functional magnetic resonance imaging 
(fMRI). Thirteen patients with CTS and 12 healthy adults were enrolled in this study. 
The authors’ findings suggest an increased and overlapping somatosensory 
representation of the affected hand in patients with CTS compared to controls.62 
Wrigley et al.63 performed fMRI studies with 41 volunteers, 20 with complete 
thoracic level spinal cord injury (SCI) and 21 controls, to evaluate the degree of 
somatosensory reorganization in the presence of neuropathic pain of patients with 
SCI. Ten of the patients with SCI had been diagnosed with neuropathic pain, while 
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the other 10 had not been diagnosed with neuropathy. The spinal level of injury was 
determined using the American Spinal Injury Association (ASIA) impairment 
classification. The mean ASIA level was T-5 for all SCI participants in this study. The 
fMRI analysis revealed that the volunteers with a complete SCI and neuropathic pain, 
showed a medial shift of the little finger representation following external tactile 
stimulation of the little finger that was statistically different when compared to control 
participants and to those with a SCI without neuropathic pain, r=-0.57, p<0.05. 
Additionally, in participants with SCI and neuropathic pain, the little finger medial 
displacement was found to correlate positively with the pain intensity, r=-0.52, 
p<0.05. In their discussion, the authors hypothesized that the observed reorganization 
may be the result of an excitatory environment due an imbalance between excitatory 
and inhibitory neurotransmitters in people living with SCI and neuropathic pain.63 
Hypothetically innocuous, or even ectopic, peripheral action potentials may travel 
along a damaged neuraxis in neuropathic pain conditions, resulting in somatosensory 
stimulus amplification and preferential integration within the CNS.  
The use of ART medications to suppress HIV replication began in the late 
1980s with zidovudine (ZDV or AZTTM), a NRTI.64 Mono-therapy was commonly 
used as ART until the arrival of protease inhibitors (PI) in the late 1990s. Effective 
HIV viral suppression is maximized by actively disrupting viral replication 
simultaneously along multiple stages of the HIV lifecycle.64 Worsening or early 
development of DSPN was common in the 1990s, and was directly associated to the 
use of NRTIs such as zalcitabine (DDC or HividTM), didanosine (DDI or VidexTM), 
and stavudine (D4T or ZeritTM) when used as monotherapy or in conjunction with 
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other ART.65-68 Animal models provided an invaluable insight into the neurotoxic 
events taking place at the peripheral nerves and their contribution to DSPN.  Many of 
the neurotoxic pathways associated with NRTIs remain speculative, but the evidence 
suggests the influence of chemokine production mediated by DRG Schwann cells.32 
Dose-dependent mitochondrial toxicity has been associated with NRTI agents and is 
likely the result of inhibition of deoxyribonucleic acid (DNA) polymerase leading to 
a direct loss of mitochondrial DNA.32,48,68-72 Dalakas et al.66 analyzed sural nerve 
biopsy samples obtained from four PLWHA and DDC-related neuropathy 
complications. Biopsy samples collected from three PLWHA and DSPN diagnosis 
never treated with DDC and from three patients with undetermined axonal 
neuropathies were used as contrasts. The samples from PLWHA and DDC-related 
neuropathy had been on DDC treatment an average of 8.2 months, and reported an 
onset of neuropathic symptoms of pain and paresthesia six to ten weeks after initiating 
DDC therapy. All of the PLWHA and DSPN never treated with DDC were not on any 
ART regimen at the time of the biopsy, although one of these participants was 
reported to have been treated with ZDV monotherapy in the past. The percentage of 
abnormal mitochondria in the axons was 54.86 ±2.47% in the samples obtained from 
PLWHA exposed to DDC therapy, 27.77 ±4.97% in the samples from PLWHA and 
DSPN never treated with DDC and 9.04±0.66% in patients with undetermined axonal 
neuropathies used as controls. The mitochondria in Schawnn cells was also analyzed 
exhibiting a similar pattern of mitochondrial abnormalities: 47.11 ±5.36% in the 
samples obtained from PLWHA exposed to DDC therapy, 19.44±5.24% in the 
samples PLWHA and DSPN never treated with DDC and 14.30±1.82% in patients 
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with undetermined axonal neuropathies used as controls. The percentage of 
mitochondrial abnormalities was found to be statistically significantly higher in the 
axonal and Schwann cell samples obtained from PLWHA exposed to DDC therapy 
when compared to either of the other two groups respectively, p<0.001.The observed 
magnitude of mitocondrial abnormalities contributes to the theory of a synergistic 
neurotoxic effect associated with NRTI exposure in PLWHA exhibiting active 
viremia. The authors also reported the presence of mitochondrial abnormalities in 
PLWHA not treated with DDC therapy, the abnormalities in those individuals may be 
solely attributed to Gp-120 neurotoxic exposure instead. 
Zhou et al.58 collected punch biopsy samples from the extremities of 101 
participants with previous or current use of NRTIs such as DDI, DDC and D4T. The 
authors aimed to investigate correlates of nerve fiber densities in patients with clinical 
signs of HIV-related DSPN. The distal site for the biopsies was the right leg, 10 
centimeters (cm) proximal to the lateral malleolus, and the proximal site was the mid-
thigh. One–hundred and one participants were enrolled in their study, 91% were men, 
60% were white, and 22% were black. The median age was 45 years old, the median 
CD4 cell count was 169 cells/mm3, and the median log viral load was 2.95. All 
participants exhibited some degree of active HIV viremia while on their respective 
ART regimens. Pain was assessed using a 0-10 visual analog scale (VAS) and the 
Gracely pain scale (GPS). The Total Neuropathy Score (TNS) was used in all 
participants. The TNS includes clinical examination tests of pin sensation, vibratory 
sensation, ankle tendon reflexes, vibratory pain threshold, heat pain threshold, cooling 
pain thresholds, nerve conduction velocities and sensory nerve action potential 
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(SNAP) amplitudes. The authors sought to evaluate the strength of the relationship 
between the TNS parameters and nerve fiber densities. Of the 101 participants, 23 
participants exhibited signs of severe loss of nerve fiber densities at the peripheral 
nervous system, defined as having less than 5 fibers/millimeter (mm) and less than 8 
fibers/mm collected from the distal and proximal biopsy sites, respectively. The 
authors also reported statistically significant reduction of nerve fiber densities in 
African American participants, with a median density of 6.60 fibers/mm compared to 
the median density of 9.98 fibers/mm for all other participants, p<0.01. The authors 
found that of the 51% participants categorized as having been symptomatic with the 
TNS score, only 30% exhibited signs of severe nerve density loss at the distal and 
proximal biopsied sites, while 53% exhibited no signs of nerve fiber loss. Conversely, 
the TNS score categorized 22% of the participants as being “neuropathy-free” while 
86% of these participants exhibited no signs of nerve fiber density loss. Small, yet 
statistically significant correlations were noted (r=0.25 to r=0.33, p<0.01) between 
distal site nerve fiber denervation and TNS score, VAS score, GPS score, toe cooling 
pain threshold, toe vibration pain threshold, and SNAP amplitudes at the sural nerve. 
Only toe cooling pain threshold sensation was found to have a significant association 
exhibiting evidence of denervation at the proximal sites of biopsies with r=-0.25, 
p=0.01. Zhou et al.58 concluded that the damage observed at the periphery is length-
dependent, predominantly concentrated in the distal extremity. The authors also 
indicated that the observed hypernociception might have been associated with 
preferential damage to small fiber dysfunction validating the diagnostic contribution 
of the clinical presentation and subjective symptomatology of DSPN over more 
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invasive nerve conduction studies of the sural nerve. The current generation of NRTI 
appears to not share the same neurotoxic properties associated with its predecessors in 
this class of ART.2,38 
In summary, the introduction of neurotoxic ART agents, such as the early 
NRTI may have a synergistic contribution to the damage associated with Gp-120 
exposure in PLWHA and symptomatic DSPN. The reductions in peripheral nerve 
densities, neurite retraction, and presence of an overexcited synaptic state along the 
normal pain pathways complicate the clinical presentation in these individuals. 
DIAGNOSIS 
The diagnosis of HIV-related DSPN is largely based on a conglomerate of 
clinical symptoms, punctuated by acute pain and hyperesthesia at the extremities.73 
Additional clinical symptoms include numbness, lower extremity cramps, allodynia, 
and severe burning.73 Paradoxically, strength at the extremities remains intact except 
for cases where disuse atrophy is present. The damage to the distal nerves is bilateral 
and length-dependent; initial DSPN symptoms would present at the toes and progress 
proximally. The rate of proximal progression varies but appears to be associated with 
HIV disease progression into AIDS. The physical examination consistently reveals 
decreased deep tendon reflexes (DTR) at the ankle and decreased threshold to 
vibratory sensation distal to the ankle joint.73 Robinson-Papp et al.74 studied the 
association of clinical signs present in HIV-related DSPN and objective clinical 
measures of vibratory sensation, pin sensitivity and DTR. The strength of the 
association between the presence of DSPN-related paresthesias and neurophysiologic 
tests of nerve conduction, quantitative vibratory threshold, and quantitative 
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temperature thresholds were also appraised. The authors collected data from a cohort 
of 237 PLWHA and DSPN. Strong associations were found between self-reported 
DSPN paresthesias and vibration sensation (OR=14.9, 95% CI 7.1-31.1, p<0.001), pin 
sensibility (OR=10.9, 95% CI 5.5-21.7, p<0.001), and DTR (OR=5.5, 95% CI 2.8-
10.6, p<0.001). Of the quantitative neurophysiologic tests performed, only the 
quantitative sensory threshold for vibration exhibited a significant association with the 
presence of DSPN-related paresthesias (OR=3.8, 95% CI 1.5-9.8, p=0.006). The 
presence of asymmetric, unilateral or symptoms preferentially affecting the upper 
extremities warrant further medical investigation to identify their etiology.73 
Blood work is helpful in ruling out neuropathies associated with diabetes, 
vitamin B-12 deficiencies, thyroid dysfunction, renal dysfunction, liver impairments 
or syphilis.73 Limited specific diagnostic tests for HIV-related DSPN are available. 
Electromyography and nerve conduction studies often fail to identify the presence of 
neuropathies as these tests exhibit low sensitivity to small fiber neuropathies.73 The 
most common electrodiagnostic protocol for DSPN tests the integrity of the sural 
nerve, with electrodes placement at the ankle and mid-calf region.75-77 The physical 
location of the testing electrodes may partially explain the lack of sensitivity of these 
tests, as the clinical symptoms of HIV-related DSPN remain largely at the toes and 
plantar aspect of foot. Loseth et al.76 reported the diagnostic properties of nerve 
conduction studies (NCS) of the medial plantar nerve in people living with diabetes-
related neuropathy. The authors collected data from 50 participants living with 
diabetes-related neuropathy and 98 age matched controls. The presence of neuropathy 
was ascertained when abnormal NCS findings in two or more nerves were detected. 
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Abnormal NCS findings, using the medial plantar nerve, were reported in 59% of the 
participants living with diabetes-related neuropathy, while the sural nerve test 
identified NCS abnormalities in 24% of the participants. The authors mentioned that 
the relatively low amplitude of the electrodiagnostic parameters collected at the 
medial plantar nerve posed technical limitations during these tests. Additionally, 
Sylantiev et al.77 reported a 91% sensitivity and 95% specificity to identify diabetes-
related neuropathic changes in nerve conductivity when using the medial plantar 
nerve protocol, compared to 55% sensitivity and 95% specificity when using sural or 
peroneal nerve protocols. 
HIV-related DSPN is characterized by the loss of distal free nerve endings.58 
Punch skin biopsies can be performed to evaluate the magnitude of neurite retraction 
present. This invasive procedure may only be indicated in limited cases, as the 
presence and frequency of clinical symptoms may suffice in confirming the presence 
of HIV-related DSPN.73  
TREATMENT 
Overview 
The International Association for the Study of Pain (IASP) defines 
neuropathic pain as “pain caused by a lesion or disease of the somatosensory nervous 
system.”78 The effective management of pain associated with neuropathies remains a 
significant challenge for providers due to the numerous possible etiologies associated 
with neuropathic pain.78 Peripheral nerve damage may arise from physical, chemical, 
virus-related, or even endogenous mechanisms affecting single or multiple peripheral 
nerves at once.79 Many of the currently approved pharmacological agents have been 
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approved for use with less than half of the participants reporting greater than 30% 
pain relief, compounding the level of complexity associated with reaching optimal 
pain management outcomes.79-81  
The IASP commissioned the Neuropathy Special Interest Group (NeuPSIG) 
for the development of analgesic treatment guidelines to manage neuropathic pain 
based on the current body of evidence in the literature.81 O’Connor et al.81 published 
an overview of these guidelines in 2009. The IASP guidelines include a clinical 
treatment algorithm as well as recommendations for first, second, and third line 
analgesic agents to use to manage neuropathy-related pain syndromes. The American 
Pain Society, Canadian Pain Society, Finnish Pain Society, Mexican Pain Society, and 
Latin American Federation of IASP have endorsed the IASP neuropathic pain 
management guidelines.81 The first line analgesic agents were chosen based on the 
Oxford center for evidence-based medicine grade “A” recommendation. The second 
line agents were selected based on multiple randomized controlled trials (RCT) 
supporting their efficacy. Finally, the third line agents were chosen if there was at 
least one positive RCT, or if the results in RCTs were deemed inconsistent or had 
earned a grade “B” recommendation. Three types of pharmacological agents were 
considered to meet the criteria for first line treatment options: antidepressants 
(tricyclic antidepressants [TCA] or serotonin-norepinephrine reuptake inhibitors 
[SSNRI]), calcium channel α2-δ ligands, and 5% concentration topical lidocaine 
application. The NeuPSIG acknowledged the necessity to consider opioids analogs as 
first line agents in certain clinical presentations of neuropathic pain, but the consensus 
of the panel was to use these agents preferentially as second line agents. A plethora of 
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pharmacological agents were considered as third line agents based on the liberal 
inclusion criteria for this category.81 The following section will review the 
recommended treatment management algorithm and the treatment agents’ 
recommendations along with their respective use in the management of DSPN related 
to HIV infection. Finally, alternative options for management of HIV-related DSPN 
pain will be proposed based on available evidence supporting their utilization. 
Clinical Treatment Algorithm 
The IASP guidelines outline a stepwise algorithm for neuropathic pain 
management. The first step consists of: confirming the diagnosis of peripheral 
neuropathy via acceptable diagnostic procedures, assessing and recording pain, 
establishing the root cause of the neuropathic condition, identifying any 
comorbidities, and explaining the cause of pain to the patient, while setting realistic 
analgesic goals based on the individual’s respective clinical presentation.81 
The second step, whenever possible, begins by initiating treatment for the 
identified underlying cause(s) for the neuropathic condition. A comprehensive pain 
and quality of life assessment is recommended. The treatment of the underlying cause 
for neuropathy is followed by the titration of approved first line medications, such as 
TCA/SSNRI, calcium channel α2-δ ligands, either alone or as combination therapy. 
The IASP guidelines endorse the early use of opioid agents in clinical cases of acute 
and severe neuropathic pain, concurrently with titration of first line medication until 
reaching their maximum analgesic effect. Lastly, non-pharmacological treatment 
options should be explored and initiated, if indicated.81 
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The third step in the clinical algorithm advises clinicians to continually re-
assess self-reported pain and quality of life. The NeuPSIG expert panel advised to 
continue with the established analgesic treatment if greater than 30% pain reduction 
from baseline is achieved with minimal or manageable side effects. If limited pain 
relief is achieved after reaching maximum titration of analgesic agents, e.g. less than 
30% pain change from baseline, providers should consider adding another first line 
agent or switching to an alternative first line medication. In cases of pain management 
failure, the NeuPSIG expert panel recommended to refer the individual to a pain 
specialist or comprehensive pain management program.81 
Antidepressants (TCA and SSNRI). Numerous RCTs have supported the 
use of TCA for the treatment of post-herpetic neuralgia pain82-85 and distal peripheral 
neuropathy pain associated with diabetes.86,87 Carbamazepine and TCAs have been 
found to be potent sodium channel blocking agents; which may explain the analgesic 
effect observed when used in clinical presentations such as distal peripheral 
neuropathy associated with diabetes and trigeminal neuralgia.85 The relative low cost 
of TCAs, once a day administration, and their favorable impact on depression, makes 
this class of medication an attractive option as a first line agent.88 Two TCAs are 
recommended in the IASP neuropathic pain management guidelines based on the 
evidence supporting their respective analgesic effect: nortriptyline (AventylTM or 
PamelorTM) and desipramine (NorpramineTM or PertrofaneTM). The aforementioned 
TCAs are preferred to amitriptyline chloride (AC or ElavilTM) as they exhibit 
decreased side effects and are more easily tolerated.81 The IASP recommends starting 
dose for TCAs of 25 milligrams (mg) at bedtime, increasing the dose every three to 
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seven days until reaching the maximum dose of 150 mg/day. An adequate TCA trial 
may last up to eight weeks, with more than two weeks at the maximum tolerated dose. 
The most common side effects associated with TCAs include: dry mouth, blurred 
vision, weight gain, and urinary retention. TCAs should be used with caution in the 
presence of cardiac disease, suicide risk, seizure disorder, and when used in 
combination with opioid analogs. In addition to their reported analgesic effect, TCA 
use has been reported to improve self-reported depressed mood and insomnia.81 The 
IASP guidelines acknowledge that TCAs have not proven to be more effective than 
placebo interventions in managing DSPN pain in HIV. In a landmark study by Shlay 
et al.,89 250 PLWHA and symptomatic DSPN were enrolled in a multi-center double 
blind placebo control RCT. The aim of this multi-center trial was to evaluate the 
analgesic effect of standardized acupuncture regimen (SAR) and AC. Each 
participating site randomly assigned research volunteers meeting the inclusion criteria 
to three experimental groups. The first group was a modified double blind 2 X 2 
factorial design of SAR, AC+SAR, and AC compared with placebo. The second 
group was a modified double blind design of SAR versus placebo acupuncture points. 
The last group was a double blind design of AC versus placebo. The participants on 
AC began titration at 25 mg/daily and were increased to a maximum dose of 75 
mg/daily over a period of three to seven days. Of the 250 participants, 136 were in the 
AC comparison, 239 were assigned to the SAR comparison, and 11 were randomized 
for the AC versus placebo contrast. The enrollment of participants took place between 
1993 and 1997. The authors did not report the immunological or viremic status of the 
participants. The authors followed the participants for 14 weeks with an interim 
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follow-up session at week six of the trial. The participants were required to record 
weekly pain logs using the GPS. The GPS scores range from “no pain” (0.0), “mild 
pain” (0.74), “moderate pain” (1.09), “strong pain” (1.36) and “severe pain” (1.75), 
using word descriptors associated with pain experiences. The most common pain 
descriptors reported in this group of participants were: “numbness/tingling” (>85% of 
participants), “aching/crampy” (40-50% of all participants), “stabbing/sharp” (35-
39% of all participants), “burning pain” (28-35% of all participants), and “throbbing” 
(12-23% of all participants). All participants scored in the “moderate pain” category 
at baseline, with scores ranging from 1.06 to 1.13. The AC group exhibited a -0.23 
mean pain score change from baseline to week six, while the mean change in the 
placebo group was -0.18. The standardized mean difference for pain at the first 
follow-up between placebo and AC was calculated to be -0.07 (95% CI -0.22 to 0.08, 
p=0.38). The AC group exhibited a -0.26 mean pain score change from baseline to 
week 14, and -0.30 mean change was observed in the placebo group. The standardized 
mean difference for pain at week 14 between placebo and AC was calculated to be 
0.00 (95% CI=-0.18 to 0.19, p=0.99). Similar mean difference changes were reported 
for the SAR groups. The authors concluded that neither AC nor SAR exhibited 
superior analgesic effects than a placebo intervention in this study. The results of this 
study remain inconclusive and somewhat controversial. The authors were unable to 
control for virological status, as the commercial test viral load tests became widely 
available in the late 1990s and early 2000s.64 Additionally, the maximum analgesic 
effect of AC may not have been reached, as the maximum dose used was 75 mg/day, 
compared to the maximum recommended dose in the current IASP guidelines of 150 
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mg/day. The data collection took place at the zenith of DDC, DDI and D4T use as 
ART.64 The exposure to NRTI monotherapy, or in combination with other ART to 
manage HIV viremia was not reported or controlled in this trial. The GPS used in this 
study is a ratio pain scale using 13 words as descriptors of pain. Its psychometric 
properties were evaluated as a global pain assessment tool, not specific to this pain 
syndrome.90 Therefore, additional studies are needed to confirm or deny the efficacy 
of TCAs in the management of painful HIV-related DSPN in the modern ART era.   
 Two SSNRIs, duloxetine (CymbaltaTM) and venlafaxine (EfferoxTM), were 
included in the IASP guidelines based on their ability to reduce pain in patients with 
diabetes-related neuropathy and based on analgesic effects sustained for over one year 
in an open label trial.81 SSNRIs have been implicated in the modulation of 
endogenous analgesic mechanisms present in the descending inhibitory pain pathways 
in the brain and spinal cord.79,91 The efficacy of duloxetine has not been reported in 
HIV-related symptomatic DSPN. Goldstein et al.91 compared the analgesic properties 
of duloxetine versus a placebo medication in patients with diabetes-related 
neuropathic pain. A comprehensive battery of pain and depression questionnaires 
evaluated the analgesic effect in their study. The pain measures included the Short 
Form McGill Pain Questionnaire (SFMPQ), worst pain rated 0-10, average pain rated 
0-10, night pain rated 0-10, Brief Pain Inventory (BPI), Beck Depression Inventory 
(BDI), and Beck Anxiety Inventory (BAI). Additionally, the self-reported quality of 
life was assessed using the Short Form 36-health status (SF-36) and Euro-Quality of 
Life questionnaires. Four hundred and fifty-seven patients with both type-I or type-II 
diabetes and pain for more than 24 hours were included in the RCT. The trial lasted 
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12 weeks. The participants were randomized to one of four groups: placebo 
administration, 20 mg duloxetine daily, 60 mg duloxetine daily, or 120 mg duloxetine 
daily. A 25% participant attrition rate was reported in this study with complete data 
obtained on a minimum of 80 participants in each group. No significant demographic 
or disease-specific differences were reported in the groups at baseline. Thirteen 
percent and 19% of participants developed intolerance to the 60 mg/day and 120 
mg/day dosages, respectively. Twenty-six percent of the participants in the placebo 
group reported greater than 50% pain reduction from baseline scores after 24 hours, 
compared to 41% of the participants in the 20 mg/day group, 49% of the participants 
in the 60 mg/day group, and 52% of the participants in the 120 mg/day group. The 24-
hour pain change was found to be statistically significant for all duloxetine groups 
against the placebo intervention, p<0.05. Significant changes were reported in the 
sensory descriptor component in the SFMPQ relating to a decrease in “throbbing 
pain” (p<0.05) in all duloxetine groups compared to the placebo group; decrease in 
“shooting pain” (p<0.001) in the 120 mg/day group compared to the placebo group; 
decrease in both the 60 mg/day and 120 mg/day groups for “stabbing pain” (p<0.05 
and p<0.001, respectively) compared to the placebo group; decrease in both the 60 
mg/day and 120 mg/day groups for “sharp pain” (p<0.001 and p<0.01, respectively) 
compared to the placebo group; and decrease in “hot-burning pain” (p<0.05) and  
“splitting pain” (p<0.05) in the 120 mg/day group compared to the placebo group. 
Fifty percent of participants in this trial described the pain as being “crampy” with no 
significant change following duloxetine use in any of the tested titrations reported to 
reduce this type of pain. The authors reported that both duloxetine 60 mg/day and 120 
 35 
mg/day dosages exhibited a significant analgesic effect when comparing all other 
outcome measures to the placebo application. Thus, the IASP guidelines recommend 
beginning duloxetine with 30 mg/day, increasing weekly to a maximum dose of 60 
mg/twice daily. The duration of an adequate trial is a minimum of four weeks. 
Duloxetine is preferred to venlafaxine as it exhibits less cardiac complications and 
fewer negative side effects associated with discontinuation, but both agents exhibit 
similar rates of hepatic complications. Caution is recommended when using either of 
these agents because of reports of increased risk of suicide and hepatotoxicity when 
used in combination with opioid analogs.81 
Calcium channel α2-δ ligands (Gabapentin and Pregabalin). Gabapentin 
(NeurontinTM) and pregabalin (LyricaTM) have been found superior to placebo 
medications in RCTs of diabetes-related neuropathic pain and in cases of post-
herpetic neuralgia related pain.82,86,87,92,93 Calcium channel α2-δ ligands are structural 
analogs of GABA and their associated inhibitory effect targets the spinal cord and 
CNS.93,94 Additionally, calcium channel α2-δ ligands have been found to modulate 
neuropathic pain by preferentially binding to α2-δ, decreasing the influx of calcium 
ions at the dendrites of neurons causing a diminished ability to secrete 
neurotransmitters.93,94 Rowbotham et al.94 enrolled 229 participants with post-herpetic 
neuralgia in a double blind RCT to evaluate the analgesic properties of gabapentin. 
The authors performed weekly follow-ups during the eight-week duration of the trial. 
The participants in this trial were primarily white, with equal number of males and 
females, and averaged 73 years of age. The participants in this study had a medical 
history of herpes zoster outbreak of at least 24 months prior to beginning this study. 
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The average pain reported at baseline using a pain intensity scale of 0-10 (0 no pain, 
10 maximum pain) was 6.5±1.7. Seventy-three percent of the participants were 
reportedly not using any pain medications, while around 23% reported using opioid 
analogs to manage pain alone or in combination with TCAs. One hundred and thirteen 
participants were randomized to the gabapentin group while 116 were randomly 
allocated to the placebo intervention group. The gabapentin group began taking 300 
mg/day, gradually increasing to a maximum of 3600 mg/day. The placebo group 
received the same number of corresponding placebo tablets as the participants in the 
active agent group. Twenty-one and 14 adverse events of increased somnolence, 
dizziness and peripheral edema were reported in the gabapentin and placebo groups, 
respectively. The primary outcome of pain was measured using an average daily pain 
scale rated from 0-10 and the SFMPQ. The secondary outcome in this study was 
quality of sleep based on self-reports and diary log entries. Quality of life scores were 
obtained using the SF-36, subject-reported global impression of change, investigator-
rated global impression of change, and the Profile of Moods States (POMS). The 
authors used an analysis of covariance (ANCOVA) for pain and sleep scores to 
determine the level of statistical significance. The baseline scores were used as 
covariates for all analyses. The authors reported a mean “average daily pain” 
difference change from baseline to eight week follow-up in the gabapentin group of -
2.1±2.1compared to a -0.5±1.6 change in the placebo group, p<0.001. The mean “pain 
change” using the total score for SFMPQ was -5.8±8.9 compared to -1.8±8.9 in the 
placebo group at the eight week follow-up session, p<0.001. The mean “sleep rating 
score” was noted to exhibit a mean change of -1.9±2.5 in the gabapentin group 
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compared to 0.5±1.9 in the placebo intervention, p<0.001. The authors reported 
reaching a maximum pain reduction in the gabapentin group at week four of the trial, 
with 65% of the participants receiving the maximum dose of 3600 mg/day and 83.3% 
of participants using at least 2400 mg/daily. The quality of life measure exhibited a 
statistically significant difference (p<0.001) between gabapentin and the placebo 
groups’ adjusted means for SF-36 “bodily pain,” SF-36 “vitality,” SF-36 “mental 
health,” POMS “total mood disturbance,” POMS “depression-dejection,” POMS 
“anger-hostility,” and POMS “fatigue-inertia.”94  
Hanh et al.95 conducted a four-week double blind RCT, followed by a two-
week open label trial in patients with symptomatic HIV-related DSPN. The objective 
of the trial was to evaluate the analgesic efficacy of gabapentin compared to a placebo 
intervention. A total of 26 patients were randomized to a gabapentin trial or a placebo 
medication. Fourteen participants completed the trial in the gabapentin group, while 
10 completed in the placebo medication. The gabapentin group began taking 400 
mg/day, which was gradually increased up to a 2400 mg/day in the blinded phase of 
the trial. The dose was then increased to a maximum of 3600 mg/day during the open 
label period. The outcomes of interest of pain intensity and sleep quality were 
evaluated using a 10 cm VAS. The authors reported a median pain change of -2.85 
from baseline pain scores, with an associated 44% pain reduction at week four of the 
trial compared to the baseline median pain scores in the gabapentin group, p<0.05. A 
non-significant median pain decrease of 29.8% was observed in the placebo 
medication group. The authors reported a median pain sleep change of -2.2 from 
baseline sleep scores, with an associated 48.9% sleep improvement at week four of 
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the trial compared to the baseline median sleep scores in the gabapentin group, 
p<0.05. No statistically significant median sleep score improvement was observed in 
the placebo arm of this study.  
The IASP guidelines recommend initiating gabapentin intake at 300 mg/day, 
increasing the dose on a weekly basis until reaching maximum pain relief or 3600 
mg/day (1200 mg/ three times daily) while monitoring the patient’s kidney function. 
The NeurPSIG experts also advised to allow for a four to eight week titration period 
and to monitor pain response until it stabilizes for at least two continuous weeks 
during the trial of gabapentin. Gabapentin has been reported to improve sleep 
disturbances and has shown to have few significant drug interactions.81   
Pregabalin is the other calcium channel α2-δ ligands recommended by the 
IASP as a first line medication to manage neuropathic pain.81 Hurley et al.96 published 
a meta-analysis including three RCTs to evaluate the analgesic efficacy of pregabalin 
against placebo agents. The population of interest was patients with diabetes-related 
painful peripheral neuropathy, and the articles selected had to have reported on at 
least one pain outcome measure to be included in the meta-analysis. The authors 
pooled the data from 728 patients in the three combined trials selected. Of the 
patients, 476 had received pregabalin, and 252 had been placed in a placebo agent. 
The pregabalin doses in those trials varied from 75 mg/day to 600 mg/day. The 
selected studies had been conducted in the United States and the follow-up periods 
varied from five to eight weeks. The weighted mean difference for the end point 
“mean pain score” was reported at 1.15 (95% CI 0.81-1.49). The patients receiving 
pregabalin were significantly more likely to reach at least 50% pain reduction with a 
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relative risk ratio (RR) of 4.05 (95% CI 1.26-1.67). The prevalence of the most 
common side effects was also analyzed. Statistically significant RR in association 
with pregabalin intake was found for “somnolence” RR 0.21 (95% CI 0.11-0.42), 
“dizziness” RR 0.22 (95% CI 0.12-0.41), and “edema” RR 0.31(95% CI 0.14-0.69). 
The authors concluded that pregabalin demonstrated a significant analgesic effect in 
diabetes-related painful peripheral neuropathy compared to placebo. Most of the 
participants in the RCTs selected reported significant pain reduction within the first 
two weeks in the trials evaluated.  
The IASP guidelines recommend to begin pregabalin intake at either 50 
mg/three times daily or 75 mg/twice a day, increasing the dose every three to seven 
days, at a rate of up to150 mg/day until reaching a maximum pain relief or 600 
mg/day (200 mg/ three times a day) while monitoring the patient’s kidney function. 
The IASP recommends a four weeks trial period of pregabalin while monitoring the 
pain response to treatment. Pregabalin has been reported to improve sleep 
disturbances and has shown to have few significant drug interactions.81   
Topical agents. Lidocaine 5% patch (LidodermTM) application is 
recommended by the IASP guidelines in cases where neuropathic pain is localized to 
a specific area or it can be used as adjunct to systemic agents mentioned above. The 
lidocaine patches are typically applied up to three times a day. Limited side effects are 
reported, and most are related to local skin irritation at the site of the patch 
application. The IASP guidelines recommend a three-week trial to maximize its 
analgesic effect.81 The efficacy of topical agents affirms the pain contribution of 
peripheral structures to the pain experienced in neuropathic conditions. Lidocaine is a 
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potent sodium-channel blocking agent, and its analgesic effect may be associated with 
the suppression of localized spontaneous ectopic activity present in hyperalgesic 
conditions.79,85,97  
The analgesic impact of topical lidocaine application in PLWHA and DSPN 
has been reported in two discordant studies. An open label trial of 5% lidocaine gel 
described positive analgesic effects associated with this topical application. Dorfman 
et al.98 recruited 27 PLWHA and DSPN who were instructed to use a daily 5% 
lidocaine gel application on their feet for two weeks. Pain outcome was measured 
using a 0-10 VAS scale. Seventy five percent of the participants reported moderate 
pain relief following this daily two-week topical application, with a mean pain 
reduction of 46% compared to baseline pain measures, p<0.001. Conversely, 
Estanislao et al.99 reported conflicting results following a multicenter crossover trial 
of a topical 5% lidocaine gel application. The authors reported data collected on 56 
PLWAH and DSPN from three different clinical sites evaluating the analgesic effect 
of a topical 5% Lidocaine gel application. The selected participants were randomized 
to begin with single daily 5% lidocaine gel application or a placebo gel for a period of 
two weeks, followed by a two-week washout period before switching the intervention 
for a final two-week period. The pain outcome was measured using the GPS. The 
participants’ pain scores were similar at baseline. The recorded pain change from 
baseline did not differ between the groups at the end of the initial two-week 
intervention period, p=0.314. No significant changes in pain were reported at the end 
of the final two-week intervention period between the groups, p=0.744. The authors 
concluded that the 5% lidocaine gel application was safe but deemed ineffective in 
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managing DSPN-related pain. The authors acknowledged the limited internal and 
external validity of the GPS in its ability to capture the pain experienced in HIV-
related DSPN. The relative short duration of the intervention, the gel application 
method (compared to a slow release patch delivery), and the relative low pain scores 
at baseline in the selected participants were outlined as additional limiting factors in 
this study. Therefore the authors suggested the need to conduct additional studies to 
evaluate the analgesic impact of topical lidocaine application on HIV-related DSPN 
using longer trial periods, parallel intervention and more specific neuropathic pain 
outcome measures. 
Opioid agonists. Opioids agonists are listed as second line medications to 
manage neuropathic pain because they exhibit greater drug interaction and 
complication including developing a physical dependence to these medications. On 
the other hand, opioid medications offer an unsurpassable analgesic advantage to first 
line medications due to their near immediate levels of bioavailability. Therefore, the 
IASP guidelines recommend their use when seeking relatively fast pain relief, while 
first line medications are being titrated to therapeutic levels. The typical dose is 
recommended to begin at 10-15 mg every four hours for one to two weeks, converting 
to a slow release formulation of the opioid analog after this initial period. A maximum 
dose for opioids agonists is not recommended and the titration should proceed with 
caution and preferably under the supervision of a pain specialist. The length of the 
adequate analgesic trial for opioids agonists is four to six weeks. The patient should 
be monitored and informed of common side effects associated with opioid agonists 
intake such as nausea, vomiting, drowsiness and dizziness.81 
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The perceived notion of providers regarding physical dependence and abuse of 
analgesic agents results in under-treatment of pain in PLWHA.100-103 Breitbart et al.100 
contrasted the difference in the perceived pain experience and quality of life of 
PLWHA with and without active injections drug use (IDU) and among active and 
inactive drug users. The authors recruited 516 volunteers from multiple HIV treatment 
centers in the New York City area. The groups exhibited similar disease and 
demographic characteristics. The overall pain experience was evaluated using the 
BPI. A Pain Management Index (PMI) was computed using the subscales of the BPI, 
pain intensity, and strength of analgesic medication prescribed. The authors reported 
that only 9.6% of IDU and 16.5% of non-IDU participants were receiving adequate 
analgesic management based on PMI scores. The difference between these groups 
was found to be statistically significant, p<0.02. Conversely, no statistically 
significant differences were found in the overall pain experience between active or 
inactive IDU participants. Additionally, PLWHA and IDU were found to have a 
higher level of psychological distress when compared to non-PLWHA and IDU 
participants, p<0.0004. The authors concluded that the pain experience of PLWHA 
does not differ between IDU and non-PLWHA and IDU and appears to have been 
generally addressed at sub-therapeutic levels in this cohort.  
Non-pharmacological treatment options. The IASP treatment guidelines 
recommend exploring and implementing alternative non-pharmacological treatment 
options to manage neuropathic pain but fail to offer examples of these options to 
clinicians.81 Few non-pharmacological interventions to manage neuropathic pain are 
reported in the literature. A growing body of evidence has focused on electrotherapy 
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modalities as adjunctive therapies to systemic analgesic agents.104-107 Electrical 
modalities application and acupuncture trials to manage neuropathic pain have been 
reported in the literature with mixed results.104-107 Julka et al.105 studied the analgesic 
effect of transcutaneous electrical nerve stimulation (TENS), the authors mailed 
questionnaires to 172 people diagnosed with diabetes and with painful peripheral 
neuropathy to evaluate the analgesic effect achieved following TENS application to 
the extremities. The analgesic effect theoretically attributed to the gate theory of pain 
where a peripheral electrical stimulation interferes with nociceptive signal processing 
at spinal segments, ultimately preventing central pain perception. The authors 
reported a 34% response rate for the self-reported questionnaires. The data sample 
was based on 58 responders to the mailed questionnaire and 24 additional patients 
who had not replied to the mailed questionnaires but who were contacted for a 
telephone interview. On average, the participants were 74 years old, had been living 
with a diabetes diagnosis for 15 years, reported painful neuropathy for eight years, 
and had been using TENS for 1.7 years.  The authors reported a self-perceived 
improvement in pain of 34±4% from baseline after TENS application in 70% of the 
participants. The baseline pain scores were reported to have decreased by 2.0±0.6 
using a 0-10 scale of pain intensity, p<0.01. The participants reported applying TENS 
to the extremities on average 1.9 times per day for at least 30 minutes each 
application. The authors failed to report the baseline or the ending pain scores for 
participants in this study.  
Kumar et al.104 studied the synergistic contribution of TENS application and 
use of TCAs to manage pain in patients with diabetes-related peripheral neuropathy. 
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The authors collected data on 26 participants who were initially treated for four weeks 
with AC to manage pain. The patients whose pain did not respond to AC 50 mg/day 
(23/26) were randomized to either a TENS or sham electrotherapy application group. 
The average age of participants was 59 years old, 10 out of 23 were males, and the 
groups reported symptomatic neuropathic pain on average for 22 months. Nine 
participants were randomized to the sham application and 14 to the TENS application. 
The pain change was assessed using a 0 to 5 pain scale that included symptoms and 
affective descriptors commonly associated with neuropathic pain. The authors failed 
to describe the psychometric properties of the pain scale. A grade of 5/5 was defined 
as the individual reporting constant, excruciating and extremely intense burning pain, 
presence of paresthesias, very disturbed night sleep, and requesting strong analgesic 
medication. To score a grade of 4/5 in this scale the participant had to report 
unbearable and intense burning pain, intermittent pain frequency, paresthesias, 
significantly disturbed night sleep due to pain, and being unable to perform daily 
activities. To score a grade of 3/5 in this scale, the participant had to report burning 
pain of moderate intensity with paresthesias disturbing the night sleep; pain described 
as distressing, pain distracting and causing difficulty in daily activities. To score a 
grade of 2/5 on this scale, the participant had to report or exhibit mild burning pains 
with or without paresthesias, uncomfortable pain most of the day, occasional pain 
during night, and some disturbance of daily activities. In addition, the patient sought 
treatment to manage pain. To score a grade of 1/5 in this scale the participant had to 
report or exhibit minimal burning pain with or without paresthesias, some discomfort 
but bearable pain, and insignificant problems during daily activities. A grade of 0/5 
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implied that the participant was void of symptoms. The pain reported at baseline was 
on average 2.8±0.3 for the sham group and 3.2±0.2 for the electrotherapy group on 
the 0-5 scale. The sham application group showed significant pain score decrease of 
0.9±0.3 from baseline, p<0.03. The TENS group showed significant pain score 
decrease of 1.8±0.3 from baseline, p<0.01. At the end of the trial the participants in 
the sham application reported 55±12% reduction in pain and overall discomfort 
compared to 66±12% in the TENS group. The combination of pain relief was reported 
to be 85% in the AC+TENS group versus 79% in the AC+sham application. The 
authors failed to report the result of the direct contrast of pain relief between the sham 
and TENS application, therefore the analgesic effect associated with TENS remains 
unknown. Furthermore, the pain scale used to evaluate the analgesic effect may have 
lacked the ability to identify subtle analgesic effects attributed to the TENS 
application.  
Galantino et al.107 suggested the presence of an analgesic effect associated 
with TENS application. The authors evaluated the pain-relieving properties of an 
electro-acupuncture TENS application to the lower extremities. The authors used the 
following acupuncture sites to apply the TENS electrodes at the lower extremity: 
dorsal aspect of first metatarsal, plantar aspect of second metatarsal, proximal aspect 
of fibularis longus, and the lateral malleoli. The authors reported pilot data collected 
from seven PLWHA and symptomatic DSPN. One of the seven participants used a 
combination ART that included DDC, and none of the participants’ virological status 
was reported. The changes in outcomes of interest were traced using the Medical 
Outcomes Survey-HIV (MOS-HIV) quality of life questionnaire and changes in the 
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H-reflex parameters. The MOS-HIV contains a pain subscale to evaluate the overall 
pain intensity. The participants were asked to use a daily TENS application for 20 
minutes for a period of 30 contiguous days. The authors reported a change in pain 
score from 8.6±2.0 at baseline to 6.14±2.5 at the end of the study. The stimulus 
threshold to elicit the H-reflex at the gastrocnemius muscle did not significantly 
change from 53.6±11 milliamperes (mA) at baseline to 61±26 mA at the end of the 
study. The H-reflex activation threshold in PLWHA and symptomatic DSPN was 
reported to have been difficult to elicit and having a longer latency. The H-reflex 
threshold of activation in non-PLWHA controls was reported to be 20±6.08 mA using 
the same apparatus and protocol. A positive association between pain reduction and 
H-reflex amplitude was reported, r=0.71. The findings imply the possible presence of 
an analgesic effect involving peripheral and spinal networks. The small number of 
participants and divergent methods and instruments used to evaluate the outcomes 
limit the generalizability and external validity of the findings supporting the use of 
TENS as a viable analgesic option to manage neuropathic pain in PLWHA.  
Positive findings have been reported following monochromatic infrared photo 
energy (MIPE) application to manage pain and improve sensation in patients with 
diabetes-related peripheral neuropathy.108-113 Ammar108 conducted a RCT to evaluate 
the analgesic properties of MIPE compared to an intervention of therapeutic exercises. 
The author reported data collected on 35 volunteers diagnosed with type-I and type-II 
diabetes. The participants had to exhibit good glycemic control as an inclusion 
criterion. The participants were randomized to a four-week trial of either a group of 
MIPE application with therapeutic balance exercises or a group subjected to a 
 47 
therapeutic balance exercises only. The author selected three outcomes measures for 
this study: pain intensity, balance and sensation. The outcome of pain intensity was 
measured using a 0-10 VAS. The balance outcome was measured using the Berg 
Balance Score (BBS). The sensation change outcome was measured using a 5.07g 
Semmes-Weinstein monofilament (SWM). The sensation was tested at the plantar 
aspect of the feet on the following sites: the great toe, fourth toe and metatarsal heads. 
A blinded investigator to the group and treatment allocation conducted the pre and 
post-treatment assessments. Eighteen participants were randomized to the 
MIPE+therapeutic exercise group and 17 to the therapeutic exercise group only. The 
participants were on average in their sixth decade of life. The groups were similar at 
baseline for diabetes-related disease characteristics, height and weight. The author 
used an ANCOVA with baseline scores as covariates to evaluate the changes 
observed. At baseline, the average pain intensity was reported at 6.2±2.1 for the 
MIPE+therapeutic exercise group and 7.3±1.1 for the therapeutic exercise group only. 
The average pain intensity at week four was 3.9±1.8 for the MIPE+therapeutic 
exercise group and 5.1±2.3 for the therapeutic exercise group only, p=0.01. At 
baseline, the average BBS score was reported at 31±9.27 for the MIPE+therapeutic 
exercise group and 28.58±10.16 for the therapeutic exercise group only. The average 
BBS score at week four was 47.61±10.16 for the MIPE+therapeutic exercise group 
and 32.52±9.54 for the therapeutic exercise group only, p=0.014. At baseline, the 
average number of sites without sensation was reported at 7.2±1.8 for the 
MIPE+therapeutic exercise group and 8.3±0.9 for the therapeutic exercise group only. 
The average number of sites without sensation at week four was 1.4±2.1 for the 
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MIPE+therapeutic exercise group and 7.2±1.3 for the therapeutic exercise group only, 
p=0.0001. The author concluded that the use of MIPE improves self-reported pain, 
balance scores, and appears to restore sensation in patients with diabetes-related 
neuropathy. The improvement in sensation was attributed to MIPE’s ability to 
improve micro-capillary circulation by inducing vasodilation for several hours after 
its application and the release of nerve growth factor within the dermis. Additional 
prospective studies with adequate post-intervention follow-up are needed to confirm 
these positive findings. 
Carpal tunnel syndrome (CTS) is, by definition, a peripheral mono-
neuropathy.62,114-117 PLWHA and DSPN and people with CTS share similar clinical 
presentation that includes complaints of hypernociception, paresthesia and allodynia. 
CTS has many possible etiologies but results in median nerve entrapment at the wrist 
triggering inflammatory mechanisms distal to the nerve entrapment.114-118 In a recent 
Cochrane database review, O’Connor et al.114 selected 21 trials involving 884 people 
to explore the efficacy of non-pharmacological treatments used in the management of 
CTS. A multitude of interventions were selected for comparison, such as the use of 
wrist splints, ultrasound modality, yoga-based exercises, nerve gliding exercises, 
magnet therapy, laser acupuncture therapy and chiropractic interventions. They 
concluded that the use of a wrist brace improved symptoms of pain with a weighted 
mean difference (WMD) of -1.07 (95% CI -1.29 to 0.85) and function WMD of -
0.55(95% CI -0.82 to -0.28). One trial reviewed was noted to have study-specific 
characteristics strictly focusing on the specific position of the wrist splint. Setting the 
splint in neutral wrist position (WMD 2.14, 95% CI 0.99 to 4.65) compared to setting 
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it at 20 degrees of wrist extension (WMD 2.43, 95% CI 1.12 to 5.28) showed no 
difference in pain reduction between either of these wrist position options. Another 
trial in the meta-analysis, also demonstrating a high bias, demonstrated no significant 
difference when using a wrist splint at night versus using the wrist splint full-time on 
function and pain in patients with CTS. Limited to no evidence of improvement in 
function and pain was reported for the use of ultrasound, yoga-based exercises, nerve 
gliding exercises, magnet therapy, laser acupuncture therapy, or chiropractic 
interventions.114 Therefore, the use of wrist splints emerges as a viable non-
pharmacological intervention to manage pain and loss of function in patients with 
CTS.  
The positive effect observed following splinting applications might be 
associated with the relative short-term immobilization of the wrist leading to local 
synaptic depression and cortical reorganization.119-121 Huber et al.120 investigated the 
inhibitory effect of 12-hour hand immobilization on motor task coordination, 
somatosensory evoked potentials (SEP), motor evoked potentials (MEP) and sleep 
slow wave activity. Slow wave activity (SWA) is present during non-REM sleep and 
represents 80% of human sleep. Fifteen normal right-handed males were enrolled in 
this study. A brief reaching task performed in the morning with the left hand was used 
to assess motor coordination. Seven participants were selected to evaluate SEP using 
a high-density electro-encephalogram (EEG) following bilateral median nerve 
stimulation. The other eight participants were used as controls in this study. The left 
arm of the participants was immobilized for 12 hours using an arm sling with a 
bandage covering the left hand and wrist. The participants were again seen in the 
 50 
evening to perform the motor task and measure the SEP. A significant correlation was 
found between SEP and ability to perform the motor task on the immobilized arm 
when comparing the kinematic observations and EEG activity r=0.82, p<0.0005. The 
SEP activity in the contralateral sensory motor cortex showed an increased latency 
(2.0±0.8ms, p<0.05) and decreased amplitude (-67.3±9.1%, p<0.005) following 
median nerve stimulation of the immobilized extremity. The MEP exhibited a 30-50% 
decrease in the peak-to-peak amplitude in the immobilized group when comparing the 
morning and evening recordings, p<0.01. A contralateral decrease in SWA amplitude 
was detected (-22.1±5.9 %, p<0.05) corresponding topographically to somatosensory 
cortex associated with hand control. The SWA change in amplitude seen in the 
immobilized participants exhibited a significant negative correlation with the 
immobilized hand for “hand path” variability during the motor task, r=-0.76, p<0.02. 
These findings suggest that a loss of coordination is observed when performing a 
volitional task following immobilization of the upper extremity. The authors 
attributed the changes observed in motor coordination, SEP and SWA to inhibitory 
neuroplastic events resulting from the short-term sensory deprivation and 
immobilization of the upper extremity. Similar results in the HIV/AIDS population 
might be found with immobilization of the lower extremities of PLWHA and 
symptomatic DSPN.122 
Pilot study. In a recent pilot study conducted by Sandoval et al.,122 the use of 
nighttime lower extremity (LE) splinting showed promising results in the 
management of pain and sleep disturbances in PLWHA. This pilot study used a 
crossover study design including 22 PLWHA and symptomatic DSPN to evaluate the 
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effects a three-week application of bilateral LE splints on pain and sleep disturbances. 
The authors recruited PLWHA and symptomatic DSPN complaining of painful night 
cramps at the calves. All of the participants were on a stable pain management 
regimen that included a combination of TCA/SSNRI and calcium channel α2-δ 
ligands. The participants in this study were initially randomized to begin with either a 
three-week bilateral LE splinting application or an upper extremity exercise program. 
A one-week washout period preceded the switch in the intervention groups for an 
additional three-week period. The outcomes of interest were the global neuropathic 
pain scale (NPS-10) score and the self-report of sleep quantified by the Pittsburgh 
Sleep Quality Index (PSQI). Participants initially randomized to the active control 
group were on average using fewer pain medications (0.80±0.92; versus 1.67±0.49, 
p=0.01) and had been living with a HIV/AIDS diagnosis on average for 11.22±3.59 
years compared to 16.83±5.76 years for those who began with the splinting 
application, p=0.02. Compliance with the exercise intervention period in this study 
was reported at 47%. A repeated measure ANOVA revealed a statistically significant 
20% decrease in pain scores after using the bilateral LE splints for three weeks, 
F(1.16)= 13.41,η2=0.456, p=0.002. A paired Wilcoxon test was used to evaluate the 
contrast comparing the PSQI scores and demonstrated a 20% decrease in sleep scores 
following the bilateral splint application, z=-2.69, p=0.004. The splint application did 
not prove superior to the exercise intervention, but this contrast was reported to be 
significantly underpowered (50%) to be conclusive. No statistically significant 
difference in pain scores was found between the pre- and post-exercise intervention, 
F(1,14)=0.085, η2=0.003, p=0.775. The study could not determine whether the source 
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of the pain inhibition was due to the application of a full contact protective sheaths on 
the LEs or the short-term immobilization at the ankle joint provided by the splints. 
The relatively small number of participants limits the generalizability of these 
findings, yet this area of research demonstrates promise with an adequately powered 
and well-designed prospective study.  
SLEEP DISTURBANCES 
Sleep disturbances are commonly reported in PLWHA, with more than 50 
percent of this population reporting some level of sleep disturbance.10-13 Self-
perceived sleep quality and quantity have been evaluated in the treatment of 
neuropathies as a measure of the somnolent side effect associated with 
pharmacological agents used to manage neuropathic pain.123 Sleep disturbances have 
been reported in HIV-related neuropathy and in patients on hemodialysis due to end 
stage renal disease (ESRD) related neuropathies.122,123 Biyik et al.123 enrolled 80 
volunteers with ESRD to participate in a study, in which the objective was to evaluate 
the analgesic effect of gabapentin and pregabalin. The authors used a crossover study 
design RCT. The participants were on hemodialysis three days per week due to 
ESRD. The authors used the PSQI as a measure of sleep quality. In the group 
randomized to receive gabapentin and pregabalin, the authors reported a baseline 
PSQI score of 8.7±4.2 and 8.8±4.6, respectively. Following a six-week trial of 
gabapentin and pregabalin, the PSQI score significantly decreased to 5.9±3.0 and 
6.1±4.2 respectively, p<0.001.  
In other cases, symptoms of drowsiness, lack of energy, and difficulty sleeping 
have been extrapolated to quantify sleep disturbances in PLWHA.10 Aouizerat et al.124 
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conducted a descriptive correlation study to quantify the impact of pain on sleep and 
other symptoms commonly reported by PLWHA. The authors enrolled 317 
participants, with 175 (55.2%) of these participants reporting some degree of pain. 
Fifty-two percent of participants had an AIDS diagnosis, 71% were on ART, 17.3% 
had less than 200 CD4 cell counts, and 50% exhibited undetectable levels of viral 
loads. The participants completed the following self-report questionnaires: the 
Memorial Symptom Assessment Scale (MSAS), the Fatigue Severity Scale (FSS), and 
the General Sleep Disturbances Scale (GSDS). The GSDS is a 21-item questionnaire 
using a 0-7 numeric rating scale for each item to rank the severity of sleep 
disturbance. The average reported GSDS score for all participants was 44.8±20.9, 
37.2±20.9 for PLWHA reporting “no pain” and 50.9±20.8 for those reporting pain. 
The difference in GSDS scores was found to be significant between the groups, 
p<0.001. The OR associated with GSDS scores was 1.45 (95% CI 1.27 to1.66), 
second only to the OR attributed to “<200 CD4 cell count” of 3.07 (95% CI 1.48 to 
6.40). The authors concluded that sleep disturbances are both common and coexist 
with pain in PLWHA. A GSDS score greater than 43 was indicative of significant 
levels of sleep disturbances in a separate group of 100 women LWHA with self-
reports of fatigue.125 
The impact of sleep disturbances on function or mobility is of particular 
interest in aging populations.126-128 Stenholm et al.127 examined the associations 
between sleep disturbances, walking speeds, and self-reported mobility in a group of 
2825 Finnish community dwelling individuals 55 years of age and older. Women 
(n=1693) outnumbered men (n=1132) in the pool of participants, p<0.001. The study 
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sample demonstrated notable differences between men and women in regards to the 
age (women were on average older than men, p<0.001), the percentage of self-
reported leisure activity time (men reporting more activity, p<0.001), smoking (men 
exhibited an increased prevalence, p<0.001), heart disease (men had an increased 
prevalence, p=0.005), depression (women reporting an increased incidence, p<0.001), 
walking speed (men walking faster, p<0.001), and mobility limitations (women had 
greater mobility limitations than men, p<0.001). Sleep duration was quantified by 
self-reports of total sleeping time in a 24-hour period. The participants were stratified 
based on their responses to a group of “short sleepers” reporting less than six hours of 
sleep, a group of “mid-range sleepers” reporting sleeping between seven to eight 
hours and a group of “long sleepers” reporting sleeping more than nine hours in a 24-
hour period. The mobility parameters were measured by using a combination of a 
timed walking distance of 6.1 meters and subjective self-reports. The walking speed 
was timed by instructing the participants to walk at their maximum walking speed; 
they could use walking aids, if necessary. The data for mobility were collected based 
on the participant’s self-reported ability “to walk 500 meters (m) without rest” and “to 
climb one flight of stairs without resting.” The participants were classified as having 
mobility difficulties if they answered in the affirmative to either of the preceding 
questions of mobility. The participants’ results were classified based on age (55-64 
years old and ≥65 years old) and gender. The authors reported a significantly faster 
walking speed in men 55-64 years old without sleeping disorders 1.77 m (standard 
error of the mean [SEM]0.02, p=0.01), without self-reported “weakness or tiredness,” 
1.83 m (SEM 0.02, p<0.001), and without excessive reported “tiredness,” 1.83 m 
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(SEM 0.02, p=0.003). The authors reported a significantly faster walking speed in 
men ≥65 years old without sleeping disorders 1.46 m (SEM 0.03, p=0.02), without 
self-reports of “weakness or tiredness,” 1.55 m (SEM 0.03, p<0.001) and without 
excessive reports of “exhaustion,” 1.49 m (SEM 0.02, p<0.001). The authors reported 
a significantly faster walking speed in women 55-64 years old without self-reported 
“weakness or tiredness,” 1.61 m (SEM 0.02, p=0.01). The authors reported a 
significantly faster walking speed in women ≥65 years old without self-reported 
“weakness or tiredness,”1.55 m (SEM 0.03, p<0.001). Conversely, a slower walking 
speed was reported in older women reporting greater than nine hours of sleep, 0.95 m 
(SEM 0.05, p=0.04). OR were calculated to evaluate the association of self-reported 
mobility and sleep disturbances. The younger men in the study exhibited a significant 
OR for those reporting “less than six hours of sleep” OR 3.62 (95% CI 1.40 to 9.37, 
p<0.05), symptoms of insomnia OR 3.88 (95% CI 1.28 to 11.81, p<0.05), difficulty 
sleeping without sleep medication OR 2.41 (95% CI 1.06 to 5.47, p<0.05) and those 
reporting fatigue OR 3.13 to 8.54 (95% CI 1.07 to 26.17, p<0.05). The older men in 
the study exhibited a significant OR for those reporting symptoms of insomnia, OR 
2.42 (95% CI 1.06 to 5.52, p<0.05) and those reporting fatigue, OR 1.92 to 3.94 (95% 
CI 1.05 to 8.84, p<0.05). The younger women in the study exhibited a significant OR 
for those reporting difficulty sleeping without sleep medication, OR 3.39 (95% CI 
1.45 to 7.94, p<0.05) and those reporting fatigue, OR 2.07 to 4.11 (95% CI 1.09 to 
9.42, p<0.05). The older women in the study exhibited a significant OR for those 
reporting “less than six hours of sleep,” OR 1.68 (95% CI 1.02 to 2.75, p<0.05), 
symptoms of insomnia, OR 2.15 (95% CI 1.27 to 3.66, p<0.05), and those reporting 
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fatigue, OR 1.84 to 4.70 (95% CI 1.14 to 8.61, p<0.05). The authors concluded that 
sleep disturbances are suspected to exert a significant impact on self-reported function 
and walking speeds in adults. The ORs associate with fatigue and increased sleep and 
correlate with increased frailty in older adults. 
FUNCTION 
Self-reports of function and functional performance measures provide 
complimentary information to assist the health care provider in fully appreciating the 
multifaceted construct of human function.129 Lee at al.129 compared the relationship 
between the Roland-Morris Disability Questionnaire (RMDQ) and a battery of 
physical performance tasks in 83 patients diagnosed with back pain. Statistically 
significant correlations were found between the RMDQ subsections corresponding to 
a physical performance battery. The authors reported absolute associations ranged 
from r=0.24 to r=0.30, p<0.05. The authors concluded that timed or distance measure 
physical performance tasks provide relevant and complimentary information to self-
reports measures of function. Similar physical performance batteries have been 
administered to quantify function in PLWHA. Simmonds et al.130 enrolled 100 
PLWHA with the objective of characterizing the performance in PLWHA and to 
examine the influence of fatigue, pain and HIV disease-specific characteristics on 
function. The participants in this study were predominantly African Americans (54%), 
males (79%), who were on average 40.70±7.49 years old and had been living with 
HIV infection for 6.77±4.17 years. The following self-report measures of fatigue and 
quality of life were administered: pain intensity using a 0-10 VAS scale, pain 
unpleasantness using a 0-10 VAS scale, Brief Fatigue Inventory (BFI), The MOS-
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HIV and BDI. The physical performance battery administered included: 50’ walk test-
fast walk, 50’ walk test-preferred speed, unloaded forward reach (FR), loaded FR, 
timed repeated sit-stand, sock donning test, timed repeated reach-up test, timed belt 
tie test, six-minute walk distance (6MWD), coin pick-up test, and pen pick-up test. 
The sample of participants was stratified based on CD4 cell counts at the time of 
enrollment, with a demarcation at 200 CD4 cells/mm3. Fifty-two of the 100 enrolled 
participants had CD4 cell counts below 200 cells/mm3. Half of the patients reported 
pain scores averaging 6.3±2.4, and 80% of these patients reported moderate pain with 
scores ≥4 out of 10. Almost all participants enrolled in this study reported some level 
of fatigue (98%), with a mean fatigue score of 5.4±2.3 using the 0 to 10 BFI scale. 
The presence of pain appeared to impact the level of performance in the participants 
in this study. In general, the participants without pain and mild fatigue outperformed 
those with no pain and severe fatigue, who in turn, outperformed those with pain and 
mild fatigue and those with pain and severe fatigue, respectively. This group of 
PLWHA was found to perform the functional battery of tests at 30-60% of the levels 
observed in healthy aged-matched individuals. The discrepancies were observed in 
tasks performed in the upright position. The participants in this study walked 
486.66±95.44 m in six minutes and were able to walk 50’ “fast speed” in 11.36±2.53 
seconds (s), compared to 602.67±107.86 m and 9.20±2.35 s respectively for non 
PLWHA aged-matched individuals. The functional battery results for older 
community-dwelling adults closely resembled the level of performance observed in 
PLWHA respectively for reach up test (3.92±0.96 s versus 4.33±1.64 s), FR 
(30.60±11.21 cm versus 34.54±7.32 cm), 50’ fast walk (11.56±2.31 s versus 
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11.36±2.53 s), sit-to-stand (3.88±1.70 s versus 5.25±2.06 s), and 6MWD 
(465.60±159.32 m versus 486.66±95.44 m). A stepwise linear regression 
demonstrated a significant contribution attributed to the self-reported pain intensity, 
6MWD and FR to the MOS-HIV scores. These predictors accounted for 26% of the 
variance observed in MOS-HIV scores, with pain intensity alone accounting for 64% 
of this variance. The authors failed to stratify the participant’s performance on the 
functional test battery based on HIV disease specific parameters, but the performance 
of all the above-mentioned tests were reduced in the presence of pain. Oursler et al.131 
collected walking distances from 43 PLWHA and reported 6MWD of 494±58 m in 
those with less than 200 CD4cell/mm3 compared to 519±98 m for those above this 
immunological threshold. Additionally, the 6MWD had a strong and significant 
correlation with oxygen consumption collected using a modified cardiovascular 
fitness assessment, r=0.60, p<0.001. A linear model including the 6MWD and the age 
of the participants accounted for 43% of the variance observed in the peak volume of 
oxygen utilization (VO2peak) in this study. The VO2peak was defined as the average of 
the last two oxygen utilization recordings during a modified Bruce treadmill protocol. 
Other linear models including the 6MWD, grip strength, body mass index, and history 
of hypertension increased the variance to >60% of the recorded VO2peak. However, the 
results lacked statistical coverage of the predictors to be generalized to all PLWHA 
due to the small number of participants enrolled in this study.  
Functional impairments have been reported in the presence of neuropathies. 
Authors have reported significant differences in gait quality, walking speed and total 
distance walked in individuals with damage to the peripheral nervous system.132,133 
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Manor et al.132 reported gait characteristics obtained from 12 patients diagnosed with 
diabetes-related peripheral neuropathy and 12 aged-matched controls. The 
participants in their study were matched for age, height, and body mass. The groups 
differed in total standing balance, stride variability, six-minute walk distance 
(6MWD) and timed–up-and-go test times. Standing balance and stride length were 
measured using force plates and kinematic analysis, respectively. Standing balance 
was obtained from the average of three consecutive 30 s trials of quiet standing with 
eyes closed. The average velocity and area of displacement of the center of mass 
(COM) was collected. The velocity of COM displacement was not found to be 
different in these groups. The area of COM displacement was found to be 
significantly different between patients with peripheral neuropathy (11.8±2.4 cm2) 
and age-matched controls (3.8±0.4 cm2), p=0.01. The stride variability was defined as 
the standard deviation from the stride duration over 30 consecutive strides observed 
while walking on a treadmill at the average walking speed obtained during the 
6MWD The stride time variability was found to be significantly different between 
people living with peripheral neuropathy (27.2±1.9 milliseconds [ms]) and age-
matched controls (19.9±1.6 ms), p=0.01. The 6MWD was 391±27 m for patients with 
diabetic neuropathy compared to 530±25 m for aged matched controls, p=0.01. The 
performance using the timed-up-and-go test was also reported, with scores of 
9.5±0.06 seconds for patients with diabetic neuropathy compared to 7.1±0.5 seconds 
for aged-matched controls, p=0.02. No significant differences in knee peak torque 
measurements were reported between these groups. The COM area displacement over 
a force place exhibited a significant inverse relationship with 6MWD (r=-0.78, 
 60 
p=0.003) and positive association with “timed-up-and-go” times (r=0.62, p=0.03) in 
patients with peripheral neuropathy. The authors concluded that ambulation distances 
and timed-up-and-go performance may improve by implementing interventions to 
reduce the COM displacement area in patients with diabetic neuropathy. Thus, a 
decreased ability to perform common physical performance tasks has been reported in 
PLWHA. The level of performance resembles that reported in older cohorts of 
individuals. Additionally, the presence of co-morbidities such as DSPN further 
impacts functional performance. The level of performance in the 6MWD and FR are 
yet to be reported for PLWHA diagnosed with DSPN. 
INSTRUMENTS 
 A multitude of measurement instruments are reported in the neuropathic pain 
literature. The lack of standardization of these measures compromises the internal and 
external validity of the reported findings. The psychometric properties of these 
instruments are often not reported. The following section will focus on evaluating the 
psychometric properties four tools that are used to measure pain (NPS), sleep (PSQI) 
and functional measures (6MWD and FR) used in neuropathic conditions. The 
aforementioned tools were selected based on each tool’s internal and external validity 
to capture its respective construct in PLWAH and DSPN. 
Pain Measure 
The VAS, numeric rating scale (NRS), GPS and the Neuropathic Pain Scale 
(NPS) have been used in longitudinal studies in HIV-associated DSPN to evaluate the 
analgesic effect of systemic and peripheral interventions. The VAS is a continuous 
pain scale, measuring 10 cm in length, and anchored by two verbal descriptors of pain 
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representing extreme opposites. The VAS has been extensively validated in different 
pain syndromes134 with high levels of test re-test reliability (r=0.94), however its 
psychometric properties have not been reported for the measurement of neuropathic 
pain. The VAS exhibits lower reported reliability in individuals with low levels of 
literacy living with arthritis-related pain, r=0.71. The minimum clinical importance 
difference (MCID) for the VAS has been reported to be 1.37 cm in a cohort of 
patients with rotator cuff injury.134 The NRS is a numeric version of the VAS, 
segmentally divided by numbers from 0 to 10. The NRS measures 11 cm in length 
with each segmental number enclosed in a 1cm by 1cm box, and anchored at each 
extreme of the scale by a pain descriptor akin to the VAS. The psychometric 
properties of the NRS are similar to those reported for the VAS. The NRS exhibits a 
test re-test reliability in rheumatoid arthritis cohorts of r=0.96 in literate participants, 
and r=0.95 in participants with low levels of literacy. A change of two points on the 
NRS is considered to be a clinically significant change in participants when 
evaluating diabetes-related DSPN, post-herpetic neuralgia and chronic low back pain 
clinical presentations.134 The GPS, also known as the Descriptor Differential Scale 
(DDS), has been used to evaluate pain outcomes in HIV-related DSPN. The DDS 
consists of 12-item pain descriptors with two 10-point scales equidistantly positioned 
on both sides of the pain descriptor, anchored at each end by a “minus” and “plus” 
signs.135 When using the DDS, the person is asked to place a check mark on either 
side of the pain descriptor using the center position as point of reference for the level 
of pain perception. The DDS psychometric properties were evaluated with the 
assistance of 91 volunteers scheduled to undergo oral surgery. The DDS has been 
 62 
validated to evaluate “sensory pain intensity” with test retest reliability of 0.73 to 
0.84, and “unpleasantness” with reliability of 0.78 to 0.90.135 These reliability score 
were obtained by asking the participants to rate their sensory pain intensity and pain 
unpleasantness levels before oral surgery and again following a one-hour retest 
interval. The minimal detectable difference for this scale and its ability to detect 
analgesic treatment effects are yet to be reported in the literature.  
Newly developed neuropathy pain specific questionnaires such as the NPS 
may provide a more comprehensive comparison of the analgesic effect differences 
between the intervention groups when compared to a placebo intervention. The NPS 
is a zero to 100 scale, divided into ten separate 0-10 subscales. The patient is asked to 
quantify the different aspects of the pain experience in the presence of neuropathies. 
Galer and Jensen136 reported that the NPS exhibits both predictive and discriminant 
validity as well as being sensitive to the effect of treatments impacting neuropathic 
pain. The NPS was developed using focus group discussions to extract the most 
common descriptors in patients with neuropathic pain. “Pain intensity” and “pain 
unpleasantness”, capturing global pain dimension, were added to the following eight 
pain descriptors, extracted from the focus group sessions and included in the NPS: 
“sharp,” “hot,” “dull,” “cold,” “sensitive,” “itchy,” “deep” and “surface” pain. Two 
hundred and eighty-eight patients were recruited to evaluate the discriminant validity 
of the NPS. The participants in Galer and Jensen136 were diagnosed with painful 
neuropathic conditions such as diabetic neuropathy (n=24), post-herpetic neuralgia 
(n=128), reflex sympathetic dystrophy (n=69), and traumatic peripheral injury 
(mononeuropathy without autonomic involvement, n=67). The results of the 
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discriminant analysis of the NPS revealed little overlap between the ten selected 
descriptors for pain in neuropathic conditions (r<0.50), with the largest correlation 
observed between the reports of “surface pain” and “sensitive pain” (r=0.73) and 
between “pain intensity” and “unpleasantness of pain” (r=0.65). The predictive 
validity of the NPS was evaluated using Bonferroni-adjusted ANOVA. The pain 
descriptors of “sharp,” “cold,” “sensitive,” and “itchy” exhibited a statistically 
significant ability to distinguish between post-herpetic neuralgia and the other 
neuropathic conditions, p<0.01. Conversely, the global items of “pain intensity” and 
“unpleasantness” did not significantly differ across the different neuropathic 
conditions. A separate cohort of 78 patients with neuropathy was used to test the NPS 
for its ability to detect change over time. All descriptors, except for the descriptor 
“itchy,” appeared sensitive to change over time following an analgesic injection of 
lidocaine versus phentolamine, p<0.01. The descriptors for “unpleasantness” and 
“deep pain” appeared to have more pronounced effect to lidocaine injections when 
compared to phentolamine injections, p<0.01. A recent study evaluated the NPS’s 
ability to detect change in pain scores in people living with diabetes-related peripheral 
neuropathy; the authors reported a statistically significant 18.6% change in the mean 
global score rating following a 5% topical application of lidocaine.137  
Galer et al.138 conducted a multi-center double blind placebo RCT to evaluate 
the analgesic contribution of a 5% lidocaine patch. The secondary goal was to 
evaluate the sensitivity of the NPS to treatment effects. The study was a parallel study 
design with a 2:1 allocation to treatment and placebo control respectively. The 
participants who met the inclusion criteria were required to have a baseline score on 
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the NPS of at least 4/10 in at least six different pain descriptors, a diagnosis of post-
herpetic neuralgia for at least one month, and allodynia present on physical 
examination. Ninety-six participants were enrolled in this trial; 67 participants were 
randomized to the lidocaine arm, and 29 to the placebo control. Two-thirds of the 
participants were females and the majority of the participants were Caucasians (85%) 
with a mean age of 74 years old.  The participants were asked to score their pain using 
the NPS at baseline and at a three-week follow-up session. The aims of the study were 
to evaluate the: 1) analgesic effect of a 5% lidocaine patch application versus a 
placebo application of an inert topical cream, and 2) the following aspects of the NPS, 
including the sensitivity of: a) the NPS scale when scored as a global score or “NPS-
10” of all items in the scale, b)the “NPS-8,” selecting only the eight pain descriptors 
present in neuropathies (excluding the global score for intensity and unpleasantness), 
c) scoring all eight items of the NPS Non-Allodonyc scale (“NPS-NA”, excluding 
“surface pain” and “skin sensitivity), and d) the “NPS-4,” which includes the scores 
for “sharp pain,” “hot pain,” “dull pain,” and “deep pain.” All of these scores were 
standardized on a 0-100 scale. The average pain change in the Lidocaine group from 
baseline to the three-week follow-up session was 29.6% for the NPS-10 score, 29.7% 
for the NPS-8 score, 31.3% for the NPS-NA score and 34.1% for the NPS-4 score. 
The average pain change in the placebo control group from baseline to the three-week 
follow-up session was 14.3%(p=0.043) for the NPS-10 score, 13.3%  (p=0.042) for 
the NPS-8 score, 13.7% (p=0.022) for the NPS-NA score and 12.4% (p=0.013) for the 
NPS-4 score. The authors reported no difference between groups for global pain 
intensity 0-10 subscale, p=0.156. The authors concluded that the scores obtained with 
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any of the NPS-scoring variants appear sensitive to detect treatment effects and 
proves superior to using a single scale of pain intensity as commonly used in other 
trials. Moreover, the significant analgesic effect observed following a topical 
application of lidocaine; a non-systemic agent, should spark future investigation of 
analgesic options directly targeting peripheral mechanisms involved in pain 
generation and pain perception. The NPS was used to quantify pain in PLWHA and 
DSPN and showed a 20 % reduction in pain scores following a three week bilateral 
splinting application.122   
Sleep Instrument 
The PSQI is a ten item questionnaire, covering the following seven 
components of sleep: subjective sleep quality, sleep latency, sleep duration, habitual 
sleep efficiency, sleep disturbances, use of sleeping medications, and daytime 
dysfunctions. The PSQI has a maximum score of 21. Buysse et al.139 reported 
sensitivity and specificity values of 89.6% and 86.5%, respectively for this scale to 
differentiate between good sleepers (participants scoring 5/21 or 24/100) and poor 
sleepers (participants scoring >5/21 or >24/100). Backhaus et al.140 evaluated the test-
re-test reliability for the PSQI by administering the test both to 76 participants with a 
clinical diagnosis of insomnia to 45 individuals without insomnia both after a two-day 
interval and following a 45-day interval from baseline testing. The authors reported a 
baseline PSQI score for the participants with insomnia of 12.5±3.8 and 3.3±1.8 for 
controls. This difference was statistically significant, p<0.0005. All subscale scores of 
the PSQI exhibited the same level of statistical significance in this comparison 
between controls and patients diagnosed with insomnia. The sensitivity of the PSQI 
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with identifying patients with primary insomnia was established at 98.7% with a 
specificity of 84.4% when using the established 5/21 cutoffs between good and bad 
sleepers. The psychometric properties of the PSQI were reported changing to 93.4% 
in sensitivity and 100% in specificity when the cut-off between good and bad sleepers 
was adjusted to 6/21. The test re-test reliability for the two-day interval was reported 
at 0.90 and 0.86 following the 45 day interval, while the internal consistency of the 
measure was reported at 0.85. The PSQI exhibited significant associations with sleep 
diaries, r>0.71, p<0.0005. The PSQI score had a low, but significant, correlation 
(r~0.30, p<0.05) to polysomnographic data collected in a sleep lab from 45 of the 
participants with insomnia. The PSQI was used to categorize the quality of sleep in 
PLWHA and DSPN and showed a 20% reduction in sleep scores following a three 
week bilateral splinting application.122 
Functional Performance Measures 
The use of physical performance tests, such as the 6MWD and FR test are of 
interest in the HIV/AIDS population. A recent study evaluating the physical 
performance of PLWHA using a comprehensive physical performance battery of tests 
identified these particular physical performance measures as exerting significant 
influence on the perceived quality of life in the presence of pain. This influence on the 
self-perceived quality of life, was only superseded in importance by the amount of 
self-reported pain in a sample of 100 community dwelling PLWHA.130 
The 6MWD has been widely used as a measure of physical endurance in 
multiple populations.141-144 The 6MWD results exhibit a high correlation to maximum 
amount of oxygen consumption.131,145 The 6MWD may be performed in many clinical 
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settings without the need for expensive equipment. The change in distance walked 
may be expressed in absolute distance or percentage change, but the absolute change 
in distance walked is preferred.145 Gremeaux et al.146 reported a sensitivity of 0.55 and 
a specificity of 0.92 for the 6MWD to identify patients with coronary artery disease 
(CAD) associated endurance limitations. The authors reported a MCID of 25 m in this 
patient cohort of 81 patients with CAD. The American Thoracic Society recommends 
considering a MCID change of 54 m as significant with a 95% confidence interval 
ranging from 37 to 71 m for individuals with chronic obstructive pulmonary disease 
(COPD). Manor et al.147 assessed the reliability of the 6MWD in patients diagnosed 
with peripheral neuropathy. The authors enrolled 20 community dwelling participants 
diagnosed with a neuropathy associated with multiple etiologies. Twelve of the 
participants were women, and eight were men with an average age of 68±12.5 years. 
The participants were instructed to walk between two cones placed 30 m apart along a 
lighted hallway. The authors reported a high intraclass correlation coefficient (ICC) 
for a single measure of the 6MWT of 0.94 (95% CI, ICC3,1 0.90 to 0.98).147 The 
6MWT was deemed reliable under these testing conditions in these patients with 
neuropathy due to multiple etiologies. 
The FR test provides the clinician with an estimate of the patient’s limit of 
stability in the sagittal plane.124,137 The loss of sensation associated with neuropathic 
conditions contributes to COM instability observed in this population.132,148 Steffen et 
al.149 reported data collected from 37 participants diagnosed with Parkinson’s Disease 
(PD) to evaluate the MCID of physical performance measures used in this population. 
The FR test was included in the functional measures of interest. The authors enrolled 
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37 participants diagnosed with PD. The 37 participants in this study exhibited a wide 
range of scores using the Unified PD Rating Scale (UPDRS), which is widely 
accepted as a measure of PD disease progression. The UPDRS scores obtained in the 
37 participants ranged from 7/176 to 70/176. The participants in this study were on 
average 71 years old. The authors reported the average of three trials mean reach of 
21±6 cm (95% CI 18 to 23 cm), with an ICC3,1 of 0.73 and MCID of 9 cm in this 
population. The ICC for the FR test ranged from 0.4 to 0.9 in different patient 
populations seeking physical therapy services.149 The MCID change using the FR test, 
when using the average of three trials ranged from 4 to 11 cm with a 95% confidence 
interval of the FR measure.149 This estimate was based on the limited reported 
psychometric properties of this test in small number of trials with greater than 30 
participants. The psychometric properties of the FR test in neuropathic conditions 
have yet to be reported in the literature.  
SUMMARY 
Peripheral neuropathy is the result of physical or chemical damage to the 
peripheral nerves. DSPN in PLWHA is mediated by HIV viremia and Gp-120 
exposure to the neuraxis. Endogenous and exogenous chemokine production damages 
the neurons and axons. This inflammatory mediated damage leads to cell death in the 
DRG, neurite damage and retraction at the periphery, astrocytosis in the spinal cord, 
and sensitization at the central processing centers. The presence of hypernociception 
in DSPN appears to be the result of action potentials generated by damaged peripheral 
nerves relaying into damaged spinal processing centers. This leads to inadequate 
limbic system integration of the peripheral signal and altered pain perception. The 
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continued incidence of DSPN in the era of modern ART may be explained by the lag 
between HIV seroconversion and HIV diagnosis, allowing for a significant period of 
exposure to neurotoxic inflammatory agents mediated by Gp-120. Based on the 
pathophysiological evidence surrounding DSPN, modern ART may prove to be a first 
line treatment option with neuroprotective properties in the presence of active 
HIVviremia. Moreover, recently developed HIV entry inhibitors targeting CXCR4 
and CCR5 co-receptors may possess neuroprotective properties by reducing 
chemokine mediated neurotoxicity in PLWHA and high levels of viremia. The 
damage observed in the peripheral nerves can be intermittent, episodic or even 
progressive over many years but can, in time, become disabling to the individual.  
The treatment of neuropathies has focused on using systemic agents such as 
TCAs, SSNRIs, calcium channel α2-δ ligands, and opioid analogs. These 
pharmacological agents exert an overall inhibitory effect on the neuraxis by 
optimizing GABAergic pathways and regulating ion channel function at the cellular 
level. Topical agents have been developed and have proven complementary to all 
systemic agents in the management of pain in neuropathic conditions. The analgesic 
effect observed following topical agent applications, such as lidocaine patches, 
demonstrates the presence of important pain generating mechanisms lodged at the 
periphery. The patient’s response to analgesic interventions should be monitored with 
discriminating tools specific to neuropathic conditions. The IASP neuropathic pain 
management guidelines consider a 30% pain reduction from baseline to be an 
effective intervention. Pain intensity may be measured using gross pain scales or more 
sensitive questionnaires developed to identify the complexity of the pain experience 
 70 
in the presence of neuropathic conditions. The NPS was developed to quantify the 
pain experience in the presence of neuropathies and has proven sensitive to change 
associated with antalgic interventions in neuropathic conditions. 
Few effective non-pharmacological interventions to manage neuropathic pain 
have been reported in the literature. The use of MIPE is emerging as a potentially 
viable electrotherapy modality to manage pain, and restore balance and sensory 
function in neuropathic conditions. The positive effects of MIPE may be associated to 
its long lasting vasodilation properties and its catalyst action on the release of nerve 
growth factor within the dermis. The use of nighttime splint application may also be 
an effective adjunctive non-pharmacological intervention to manage neuropathic pain. 
Paralleled evidence supporting its use is reported in CTS conditions. The analgesic 
effect of the lower extremity splinting applications may be attributed to the inhibitory 
effect associated with short-term immobilization of the limb triggering neuroplastic 
events in the CNS. A pilot-study evaluating LE splinting to manage pain and sleep 
disruptions in PLWHA may attest to the presence of this additive analgesic effect. 
The IASP treatment guidelines for the effective management of neuropathic pain 
recommend a stepwise introduction of analgesic agents, allowing a four to six week 
trial period to evaluate their respective efficacy of said agents.  
Sleep disturbances associated with peripheral neuropathy have been reported 
in the context of evaluating the impact of the somnolent side effects associated with 
the use of systemic analgesic agents. Sleep quality questionnaires such as the PSQI 
exhibit discriminant psychometric properties and help to quantify the quality of sleep  
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in neuropathic conditions. Sleep disturbances have been associated with impacting 
ambulation parameters in adults.  
Functional changes have been associated with neuropathic conditions 
resulting in decreases in gait speed, gait quality, and overall physical endurance. 
These functional changes may have an additive effect in HIV-related neuropathy 
conditions. A decrease in the overall functional mobility efficiency is observed in 
PLWHA when compared to age-matched seronegative peers. Physical performance 
tests such as the 6MWD and FR test can be used to quantify the construct of function 
in neuropathic conditions. These tests are easy to perform in clinical settings and their 
results have been reported to exert a significant influence on the self-perceived 
quality of life in PLWHA. Limited information is available regarding the impact of 
pain and sleep disturbances on function in people living with HIV-related DSPN. 
Future research endeavors should strive to categorize pain, sleep and 
functional status of PLWHA and DSPN. Indeed, few reports are available in the 
literature to guide the development of prospective studies and to evaluate 
interventions aiming at addressing pain, sleep and functional status. The magnitude of 
functional loss in the presence of DSPN in PLWHA remains unknown, but studies in 
similar neuropathic conditions suggest its presence. Pain and sleep disturbances have 
been reported to impact function in various populations. Exploring the strength of the 
association between these variables would provide a greater insight into the life 
experience in PLWHA and DSPN. Viable non-pharmacological options to manage 
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DSPN are needed to lessen the pharmacological burden placed on PLWAH. Finally, 
prospective studies are needed to evaluate the viability of non-pharmacological 
treatment alternatives, such as lower extremity nighttime splinting to manage pain and 
sleep disruptions in DSPN.  
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CHAPTER III 
 
PAIN, SLEEP DISTURBANCES AND FUNCTIONAL LIMITATIONS IN PEOPLE 
LIVING WITH HIV/AIDS-ASSOCIATED DISTAL SENSORY 
 PERIPHERAL NEUROPATHY 
A Paper To Be Submitted For Publication in Rehabilitation Oncology 
Roberto Sandoval 
 
INTRODUCTION 
Pain and sleep disturbances are commonly reported in people living with 
chronic systemic diseases such as fibromyalgia, arthritis, chronic liver disease and 
human immunodeficiency virus (HIV) infection.1-3 Data collected from a cohort of 
317 people living with HIV and the acquired immunodeficiency syndrome (AIDS), 
indicate that 55% of them experienced and ranked increases in pain and sleep 
disturbances among the top four symptoms associated with living with HIV 
infection.4 Pain and sleep disturbances were only preceded in prevalence by self-
reports of fatigue and drowsiness in people living with HIV and AIDS (PLWHA). A 
review of systemic diseases’ impact on sleep, suggests that increases in sleep 
disturbances are associated with HIV disease progression into AIDS.5 
Functional limitations have been reported in PLWHA compared to age-
matched seronegative individuals. Simmonds et al.6 reported approximately a 30% 
decrease in the six-minute walk distance (6MWD) for PLWHA compared to age-
matched seronegative individuals. More importantly, the authors described a 
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relationship between pain, 6MWD and average forward reach (FR) distance that 
accounted for 26% of the variance in self-reported quality of life. Additionally, 
significant decreases in gait quality, walking speed and 6MWD in individuals living 
with a diagnosis of peripheral neuropathy compared to age matched control cohorts 
have been reported.7,8   
Distal sensory peripheral neuropathy (DSPN) is among the most common co-
morbidities associated with long-term survival with HIV infection. Thirty to 60% of 
all PLWHA may develop clinical symptoms of DSPN as the disease progresses into 
AIDS.9-12 Pain and paresthesias at the extremities, loss of vibratory sensation, and 
decreased deep tendon reflexes are the defining clinical symptoms for the diagnosis of 
DSPN.13 The impact of pain manifestation in HIV-related DSPN on function and 
sleep disturbances has yet to be reported in this clinical cohort. The purpose of this 
study is to describe pain, function and sleep disturbance characteristics and the 
strength of their respective relationship in PLWHA and DSPN. 
METHODS 
Inclusion and Exclusion Criteria  
Adult PLWHA from an outpatient public clinic associated with the Harris 
Health System (HHS) were recruited to participate in this study. This study was part 
of a two-group design intervention study. All participants had a clinical diagnosis of 
symptomatic bilateral lower extremity DSPN. The participants were English-
speaking, on both stable pain and antiretroviral (ART) regimens. Eligible participants 
reported at least one of the following clinical symptoms: paresthesia, dysesthesia, or 
night cramps in the lower legs. Participants were excluded if they had a concurrent 
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clinical diagnosis of: significant cardiovascular or pulmonary disease, paraplegia, 
hemiplegia, diabetes, sleep apnea, or were pregnant. 
Pain Measure 
A composite pain score was collected using the self-reported Neuropathic Pain 
Scale (NPS). On this zero to 100 scale, the participant is asked to quantify the 
different aspects of the pain experience in the presence of neuropathies. Galer et al.14 
reported that the NPS exhibits both predictive and discriminant validity as well as 
being sensitive to the effect of treatments impacting neuropathic pain. The NPS may 
be scored in four different ways. It may be scored as a global score or “NPS-10” 
including all items in the scale. It can be scored as the NPS-8 selecting only the eight 
pain descriptors present in neuropathies, excluding the global scores for pain intensity 
and unpleasantness. It can be scored as the NPS non-allodonyc (NPS-NA) scale using 
the eight items of the NPS but excluding “surface pain” and “skin sensitivity.”  Lastly, 
it can be scored as the NPS-4, which includes the score for “sharp pain,” “hot pain,” 
“dull pain,” and “deep pain.”15 Galer et al.15 reported that the scores obtained with any 
of the NPS scoring options appear sensitive to detect treatment effects. All scoring 
options of the NPS and pain intensity were included in the analysis to evaluate their 
ability to capture the construct of neuropathic pain in PLWHA and DSPN.  
Sleep Quality and Quantity 
The Pittsburgh Sleep Quality Index16 (PSQI) is a ten-item questionnaire which 
covers the following seven components of sleep: subjective sleep quality, sleep 
latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping 
medications, and daytime dysfunctions. Each of the seven subscales has a maximum 
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score of three, with a high score on the PSQI being indicative of poor sleep quality. 
Buysse et al.16 reported sensitivity and specificity values of 89.6% and 86.5% 
respectively for this sleep scale in identifying good (PSQI score <5/21) and poor 
sleepers (PSQI score ≥5/21). 
Functional Tests 
Forward reach (FR) test. For the FR test, the investigator collecting data 
asked the participants to stand next to a wall without shoes, with their feet positioned 
hip-width apart on the floor, and with the self-selected shoulder not touching the 
adjacent wall-mounted yardstick. The starting point for each reaching attempt was 
identified along a yardstick affixed to the wall by locating the ulnar styloid process of 
the arm closest to the wall. The participant was instructed to: “Please reach as far 
forward as possible.” The translated distance of the distal aspect of the styloid process 
was recorded as a reaching trial. The average distance of three reaching trials was 
recorded in centimeters (cm).  
Six-minute walk distance (6MWD). For this test the participants were 
instructed to: “Please walk as far, as fast and as safely as you can for up to six 
minutes.” The walking test was performed on a level surface void of obstacles and 
with a pre-determined path of 10.36 meters (m) path, 20.72 m per lap, requiring a 180 
degrees turn each end. The single-trial 6MWD was recorded. 
The 6MWD and the FR distance were collected using the same methods used 
by Simmonds et al.6 Both the 6MWD and FR tests have exhibited inter-session intra-
class correlation coefficient values greater than 0.83.17 The minimal clinical important 
difference (MCID) for the 6MWD has been reported to be 54 m (95% confidence 
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interval [CI] 37 to 71 m).18-20 The FR distance has been reported to have a MCID of 2 
cm (95% CI 4-11 cm).21,22 Lastly, the 6MWD, FR, in conjunction with self-reported 
pain have been reported to exert significance influence on the self-reported quality of 
life in PLWHA.6 
Procedures  
All participants signed an informed consent form approved by the institutional 
review boards of Harris Health System and Texas Woman’s University. Baseline 
demographics and HIV disease markers were collected to describe the participants in 
this study. The participants completed the NPS and PSQI questionnaires. The physical 
performance tests immediately followed the self-reported questionnaires completion. 
Data Analysis 
The data analysis was performed using the Statistical Package for the Social 
Sciences (SPSS) version 16.0 (IBM, Armonk, NY, USA). Descriptive statistics were 
computed on all variables. A correlation matrix was developed and consisted of both 
Pearson (r) and Spearman (rs) correlation coefficients for parametric and non-
parametric data, with an alpha level for significant associations set at 0.05. For further 
analysis, all data collected was screened for extreme values. Histograms and scatter 
plots were obtained and analyzed for assumptions of normality. The analysis of 
extreme values was performed using a residual analysis on the data retained for final 
analysis.  
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RESULTS 
Participants 
Informed consent was obtained on 46 community dwelling PLWHA. Data was 
collected on 45 participants. One participant failed to disclose a recent diagnosis of 
type II diabetes and was excluded from the analysis. The majority of participants were 
African American males in their fifth decade of life, living with HIV infection an 
average of 10.82 years. The most common ART used by the participants was once 
daily Atripla.TM Thirty-six of the 45 (80%) participants were on an ART containing at 
least one nucleoside reverse transcriptase inhibitor agent. Twenty-one (47%) of the 
participants were on an ART containing at least one protease inhibitor agent. Eighteen 
(40%) of the participants were on an ART containing at least one non-nucleoside 
reverse transcriptase inhibitor agent. One participant (2%) was using an ART 
containing an integrase inhibitor, but none of the participants’ ART included entry 
inhibitors. Undetectable viral load levels (<48 copies/ml) were noted in 31 (69%) 
participants in this study. The participants’ characteristics for all dependent variables 
are reported in Table 3.1. A participant’s average FR distance was 63.07 cm, which 
was greater than three standard deviations (SD) distance from the mean distance 
reached by the rest of the participants. This participant’s contribution to the FR 
distances was excluded from further analysis. No extreme values were identified for 
pain, sleep, or walking endurance scores.  
The average score for all PSQI subscales are represented in Figure 3.1. The 
average pain intensity and pain scores using the NPS, and its scoring variants are 
depicted in Figure 3.2. The average pain scores obtained reflect moderate to severe 
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pain experienced in PLWHA and DSPN. With the one outlier removed, the average 
FR distance was clustered around the mean of 36.07 cm. The 6MWD varied greatly in 
this sample of PLWHA, with a mean distance walked of 243.99 m. This mean 
ambulation distance represents a 40% reduction in distance walked than previously 
reported mean ambulation distance measured in PLWHA using similar methods.6  
The 6MWD data point distribution revealed the presence of a bimodal 
distribution with a virtual threshold at 250 m, see Figure 3.3. The group of 
participants was stratified based on the 6MWD: a group of participants with walking 
distances above 250 m (n=21, 380.05±58.42m), and a group of participants walking 
less than 250 m (n=24, 127.90±70.00m). A sub-analysis of the 6WMD groups 
confirmed the presence of two independent groups based on the participant’s ability to 
walk above or below 250 m, t(43)=-12.84, p<0.0005. The participants that were able 
to walk more than 250 m exhibited longer FR distances (39.47±7.14cm) than those 
walking less than 250 m (33.22±6.40cm), t(42)=-3.07, p=.004. The walking distance 
groups were significantly different based on the gender distribution, z=-2.31, p=0.021. 
Fourteen of the 19 (74%) women in the study were included in the group being able to 
walk below 250 m in six minutes, compared to 5/19 (26%) in the group of participants 
walking more than 250 m in six minutes. The global PSQI scores appeared higher in 
the group of participants being able to walk less than 250 m (15.79±4.06), compared 
to those walking more than 250 m (13.29±4.21), z=-1.96, p=0.05. All other 
descriptive variables failed to reach a level of significance below 0.05 for this sub-
analysis. 
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Associations 
Bivariate correlations were obtained between the descriptive variables. A 
significant inverse association was found between the number of CD4 cells and the 
PSQI scores, rs=-0.33, p<0.05. The amount of CD4 cell counts also exhibited a 
significant inverse relationship between the scores obtained in the PSQI subscales of 
sleep latency (rs=-0.35, p<0.05) and sleep duration (rs=-0.36, p<0.05). Men in this 
study exhibited longer 6MWD, rs=0.39, p<0.01. No significant associations were 
found between the age of the participants and sleep scores, pain scores, 6MWD and 
average FR distance, p>0.05. Only the sleep latency subscale exhibited a significant 
association with the 6MWD, rs=-0.32, p<0.05. The number of years living with 
HIV/AIDS was inversely associated with PSQI scores (rs=-0.36, p<0.05), scores in 
the PSQI subscale of sleep latency (rs=-0.33, p<0.05) and sleep efficiency (rs=-0.35, 
p<0.05). No significant association was found between the sleep scores and self-
reported pain intensity scores, p>0.05. As predictable, sleep scores were correlated 
with each other, as were pain measures. In addition, pain and sleep scores were 
generally associated (rs>0.40, p<0.01), though not in respect to daytime dysfunction 
scores and use of sleep medications, p>0.05. The FR and 6MWD were also associated 
(r=0.46, p<0.01), but neither was significantly associated with pain or sleep scores on 
any consistent manner. Refer to Table 3.2 for all correlations coefficients between 
sleep, pain and functional performance. 
DISCUSSION 
Pain, sleep and function characteristics presented in this study provide us with 
greater insight into the association between pain, sleep disturbances and function in 
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PLWHA with a diagnosis of DSPN. The data collected in the current study suggest 
that PLWHA and DSPN live in moderate to severe pain, are poor sleepers and exhibit 
limited ambulation distance. The average NPS-10 in the current study was greater 
than 60/100.  Galer et al.23 suggest that a NPS-10 score greater than 43/100 may 
indicate the presence of neuropathic conditions. All of the participants in this study 
had PSQI scores greater than 5/21, classifying them as poor sleepers. The average 
sleep score recorded in the current study sample is nearly 17% higher than the one 
reported in cohorts of people living with insomnia.24 The data collected in the current 
study suggests that sleep quality is influenced by lower CD4 cell counts and longer 
duration of HIV/AIDS. These findings are similar to those reported by Lee et al.4 
where the authors found significant sleep disturbances in PLWHA, which increased 
with HIV infection progression into AIDS. Long-term survival with HIV infection 
exhibited an inverse relationship with sleep scores, perhaps suggesting an adaptation 
to chronic sleep disturbances in this cohort. Galer et al.15 indicated an increased 
sensitivity and discriminant validity of the NPS score in all of its scoring options 
(NPS-10, NPS4, NPS8, NPSNA) over those obtained using the self-reported pain 
intensity alone. In the current study, pain intensity scores alone did not exhibit a 
significant association with functional performance tests, pain, and sleep scores. 
Conversely, a small yet significant association was found between NPS and PSQI 
scores, suggesting that these variables represent different but related constructs. These 
findings suggest that future researchers may opt to use any of the NPS scoring 
options, as they appear equivalent in capturing the construct of pain in PLWHA and 
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DSPN. Using shorter versions of self-reported questionnaires has an added advantage 
of reducing the burden on future study participants. 
The recorded 6MWD represents 60% of the distance walked reported in 
previous PLWHA cohorts,6 albeit large variability was noted in the current sample of 
participants with DSPN for this variable. The results of the 6MWD distance revealed 
the presence of two independent groups based on their walking distance. Manor et al.7 
reported an average 6MWD of 391±27 m collected on a sample of 20 sexagenarian 
volunteers living with neuropathic conditions due to multiple etiologies. The current 
6MWD collected in younger participants, appears to be 40% lower than those 
previously reported in people living with neuropathy not associated with HIV 
infection.7 The results of the 6MWD stratification based on the participant’s ability to 
walk 250 m, suggest that women with HIV-related DSPN may exhibit greater 
functional disadvantages and sleep disturbances compared to men. The lack of 
homogeneity of the sample from Manor et al. 7 may also account for the discrepancy 
in 6MWD. The data collected in this sample of PLWHA with HIV/AIDS-related 
DSPN suggest that the distance walked was most influenced by sleep efficiency, 
defined in the PSQI as the ratio of the number of hours slept divided by the number of 
hours in bed. The average PSQI-sleep efficiency in the current study was calculated at 
60.93±32.27% compared to a higher efficiency score of 80.30±12.90% in people with 
a clinical diagnosis of insomnia.24 The associations between CD4 cell count, years 
living with HIV diagnosis and pain appear to exert significant influence on self-
reported sleep quality. Sleep quality in turn was reported to influence the 6MWD; 
therefore, a possible correlation matrix centered on self-reported sleep quality 
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emerges. Future studies are needed to confirm the strength of these associations and 
the presence of the proposed matrix centered on self-reported sleep quality. 
The average FR distances recorded in this sample of PLWHA and DSPN 
appeared to be associated only with the 6MWD and not by pain or sleep disturbances. 
Manor et al.7 reported significantly increased oscillations of the center of mass 
(COM) during quiet standing in individuals with diabetic neuropathy. The current 
study focused on the participants’ ability to volitionally control the COM along the 
sagittal plane while reaching forward. The average FR distances reported in the 
current study suggest a normal ability to perform this reaching task compared to 
seronegative aged matched individuals (34.73±7.54 cm).6 Lastly, the average 
recorded FR distance suggest a very low risk for falls in this cohort of participants.22 
This current study was limited by its inability to confirm the DSPN diagnosis 
with more invasive clinical tests such a punch skin biopsies. Additionally, all of the 
participants were recruited at a public outpatient clinic where the demographic 
characteristics may differ from those PLWHA and DSPN followed in private practice 
settings. PLWHA with recent HIV/AIDS diagnosis may not have been adequately 
represented. Finally, unilingual Spanish-speaking PLWHA may have been 
underrepresented in this study as the questionnaires used have only been validated in 
their English version. 
SUMMARY 
 Pain, sleep and functional disturbances are a common occurrence in 
HIV/AIDS related DSPN. The data reported in the current study suggest the presence 
of significant relationships between the constructs of pain, sleep disturbances, and 
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function. Of particular interest is the high PSQI scores recorded in PLWHA and 
DSPN, which were found to be 17% higher than those reported in people living with 
clinical diagnosis of insomnia. The 6MWD in PLWHA and DSPN appears to be 
associated with sleep disturbances and not self-reports of DSPN-associated pain. 
Future studies should validate the proposed matrix of function, pain and HIV disease 
factors with self-reported sleep quality in the center. Paradoxically, the results of the 
FR test suggest a normal ability to volitionally translate the COM along the sagittal 
plane, and exhibited a significant association with the 6MWD. The latter may suggest 
the presence of separate yet related constructs of physical endurance and balance. 
Finally, significant gender differences in function were observed in the current study 
that would warrant further investigation. 
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CHAPTER IV 
 
LOWER EXTREMITY SPLINTING TO MANAGE NEUROPATHIC PAIN AND 
SLEEP DISTURBANCES IN PEOPLE LIVING WITH HIV/AIDS 
A Paper To Be Submitted For Publication in Pain® 
Roberto Sandoval 
INTRODUCTION 
Distal sensory peripheral neuropathy (DSPN) is among the most common 
complications associated with long-term survival with the human immunodeficiency 
virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). HIV-related 
DSPN has been reported in 30 to 60% of all people living with HIV and AIDS 
(PLWHA).1-4 DSPN in PLWHA appears to be mediated by HIV glycoprotein-120 
exposure to the neuraxis, leading to chemokine production. The inflammatory mediated 
peripheral nerve damage leads to cell death in the dorsal root ganglia, neurite damage, 
retraction at the periphery, astrocytosis in the spinal cord, and sensitization at the central 
processing centers.5,6  
Neuropathic pain is predominantly managed by using systemic agents such as 
antidepressants, calcium channel α2-δ ligands and opioid analogs.7,8 These 
pharmacological agents exert an overall inhibitory effect on the neuraxis by optimizing γ-
aminobutyric acid (GABA) agonists pathways and regulating ion channel function.7,9 The 
direct analgesic effect attributed to topical agents, such as topical lidocaine application, 
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demonstrates the presence of peripheral pain generating mechanisms.8,10,11 None of the 
aforementioned systemic agents have demonstrated superior analgesic effects to placebo 
interventions in HIV-related DSPN.7 
In addition to pain, sleep disturbances have been reported in people living with 
end stage renal disease-related neuropathies and HIV-related DSPN.12,13 A review of 
systemic diseases’ impact on sleep suggests that alterations in sleep stages and increases 
in sleep disturbances are associated with HIV disease progression into AIDS.14 The 
impact of DSPN-related pain on self-perceived sleep quality remains uncertain, based on 
the limited number of reports in the literature. 
In a recent pilot study,13 the use of night time lower extremity (LE) splints 
showed promising results in the management of pain and sleep disturbances. This pilot 
study was a crossover study design that included 22 PLWHA and DSPN. The authors 
evaluated the effects of a three-week bilateral LE splint application on self-reported pain 
and sleep quality. A 20% improvement in both pain and sleep scores was reported at the 
end of this trial with a moderate effect size for pain and sleep scores. That study could not 
determine whether the analgesic effect was due to the application of a full contact 
protective sheath on the lower leg or the short-term immobilization at the ankle joints 
provided by the splints. The purpose of this study was to evaluate the impact of wearing 
bilateral LE splints compared to a parallel intervention of wearing bilateral LE splint 
liners only on pain and sleep disturbances in PLWHA and DSPN. The null hypotheses 
are that:  
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1) there is no difference in pain scores between individuals wearing bilateral LE splints 
and those using the splint liners only, following a three and six-week night time use 
protocol, 2) there is no difference in sleep scores between individuals wearing bilateral 
LE splints and those who wore splint liners only, following three and six-weeks of night 
time use, and 3) there is no difference in pain scores between baseline scores and 
following a six-week night time LE splints use protocol to manage DSPN-related pain. 
METHODS 
Inclusion/Exclusion Criteria  
Adult PLWHA from an outpatient public clinic associated with the Harris Health 
System (HHS), Houston, Texas were recruited to participate in this study. All participants 
had a clinical diagnosis of symptomatic DSPN. The participants were English-speaking 
and on stable pain and antiretroviral (ART) regimens. The eligible participants reported 
at least one of the following clinical symptoms: paresthesia, dysesthesia, or night cramps 
in the lower legs. Participants were excluded if they were pregnant, had a concurrent 
diagnosis of: cardiovascular or pulmonary disease, paraplegia, hemiplegia, diabetes or 
sleep apnea. 
Intervention Equipment 
Walkabout™ splints (Don Joy Orthopedics, Vista, CA, USA) were used in the 
splint group. The Walkabout™ splint is composed of a soft liner coupled to a 90 degrees 
rigid plastic exoskeleton to immobilize the foot and ankle. The plantar aspect of the 
Walkabout™ splint is fabricated with a rocker bottom allowing for ambulation. The 
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liners from the Walkabout™ splints were fitted to the participants in the splint liner 
group.  
Dependent Outcome Measures 
Pain measure. A composite pain score was collected using the self-reported 
Neuropathic Pain Scale (NPS).15 In this 0 to 100 scale, the participant is asked to quantify 
the different aspects of the pain experience in the presence of neuropathies. Galer et al.15 
reported that the NPS exhibits both predictive and discriminant validity as well as being 
sensitive to the effect of treatments impacting neuropathic pain.  
Sleep quality and quantity. The Pittsburgh Sleep Quality Index (PSQI) is a ten-
item questionnaire covering the following seven components of sleep: subjective sleep 
quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of 
sleeping medications, and daytime dysfunctions.16 Each of the seven subscales has a 
maximum score of three; a high score on the PSQI indicates poor sleep quality. Buysse et 
al.16 reported sensitivity, specificity and kappa agreement values of 89.6% , 86.5%, and  
0.75, respectively, for this sleep scale in identifying poor sleepers (global PSQI score 
>5/21). 
Procedures  
All qualifying participants signed a consent form approved by the HHS and Texas 
Woman’s University institutional review boards. Baseline demographics and HIV disease 
markers were collected to describe the participants in this study. The participants 
completed the NPS and the PSQI questionnaires. The primary assessor (RS) performed 
all data collection. After baseline completion of questionnaires, the participants were 
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randomly assigned to either the complete splints or liners only group. A pre-coded table 
was used to randomize the participants to either group, blinding the participants to the 
group allocation at baseline. The researcher individually fit all participants with either 
bilateral WalkaboutTM splints or bilateral WalkaboutTM splint liners according to their 
group assignment. Both groups received the same instruction to wear their devices at 
night while sleeping. The participants were asked to return to the clinic at week three and 
week six from baseline, to complete the NPS and PSQI questionnaires again. All 
participants were contacted weekly by telephone to record compliance with the protocol 
procedures and to document issues concerning the wearing of the splints or liners. 
Data Analysis 
Data analysis was performed using the Statistical Package for the Social Sciences 
(SPSS) version 16.0 (IBM, Armonk, NY, USA). Descriptive statistics were computed on 
all variables. To evaluate group equivalence at baseline, all descriptive and outcome data 
were analyzed for extreme variables using histograms, scatter plots and residual analysis. 
Interval and ratio-level data were compared using independent student-t tests. Mann 
Whitney U-tests were used to appraise the equivalence of the groups at baseline for non-
parametric data. The null hypotheses were tested using two separate 3X2 repeated 
measures analysis of variance (ANOVA) for the dependent variables of pain and sleep 
scores, with time (3 levels) by group (2 levels). The parametric version ANOVA was 
utilized for the pain scores, and the non-parametric version (Kruskal-Wallis) ANOVA 
was utilized for the sleep scores. The level of significance was split, with α set at 0.04 for 
the pain score analyses and α set at 0.01 for the sleep scores. The weighting of the alpha 
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allocation primarily for the pain scores and less for the sleep index scores was done to 
optimize the statistical power for the factor pain. The NPS is comprehensive, specific and 
sensitive to change in the presence analgesic interventions targeting neuropathic pain, 
whereas the sleep index scores’ psychometric properties have not been so extensively 
examined.17 
An ANOVA was used to test the null hypotheses that: 1) there is no change in 
pain and sleep scores following six weeks of bilateral splinting application compared to a 
liner application and that 2) there is no difference in pain scores following a six week 
bilateral splinting application. Each of the above mentioned ANOVAs were followed by 
two planned contrasts of interest: two between-group contrasts and a single additional 
within-group contrast of interest in the splint group. The two between-group contrasts 
focused on identifying the difference in pain and sleep scores at week three and six 
between the splint and the liner groups. The within-group contrast evaluated the 
difference in pain scores between the baseline and those recorded at week six in the splint 
group. Each pain score contrast of interest was tested using an adjusted level of 
significance, α<0.013 (or 0.04/3). The sleep score contrast was tested at an adjusted level 
of significance of α<0.005 (or 0.01/2). Lastly, an intention-to-treat analysis was 
conducted on the outcome variables of pain and sleep scores to mitigate the attrition rate 
impact on the data collected. For the participants who discontinued the trial at baseline, 
the baseline scores were transposed for week three and six. For those participants missing 
follow-up visit data, the average outcome variable scores for their available data was used 
to impute the missing information. 
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RESULTS 
Participants 
Data were collected on 46 community dwelling PLWHA. The participants were 
equally randomized to either the splint (23/46) or the liner (23/46) groups. One 
participant in the liner group failed to disclose a recent type-II diabetes diagnosis and was 
excluded from the study, with none of the data used in the analyses. Thus, 45 participants 
began the study, 23 in the splint group and 22 in the liner group.  
The overall attrition rate in the splint group was around 35%. Three participants 
(13%) discontinued participation within the first week of the study for personal reasons 
and three additional participants (13%) failed to return for all follow-up sessions. Two 
additional participants (9%) in the splint group had incomplete data, missing one follow-
up session. Thus complete data were collected on 16 of the 23 participants (70%), and 
incomplete data on two additional participants (9%) by the end of the trial. The 
incomplete data of these participants were included in the contrast of interest analysis 
comparing the pain and sleep scores between baseline and week six measures and 
between the intervention groups at week six.  
For those in the liner group, one participant (7%) failed to report for all follow-up 
sessions, two additional participants (9%) failed to report for the final follow-up session. 
Complete data were obtained for 19/23 (83%) participants in the liner group and 
incomplete data for two additional participants. The data collected at week three and six 
of the trial was used for the contrasts of interest comparing the pain and sleep outcomes 
between the intervention groups. 
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The researcher attempted to contact the participants who discontinued the trial in 
both groups, but was unable to reach the participants using the provided contact 
information. The study attrition and number of subjects kept for final analysis is depicted 
in Figure 4.1. 
The majority of the participants were African American males in their fifth 
decade of life, and had been living with HIV infection on average for 10.82 years. The 
most common ART used by the participants was once daily formulation of 
emtricitabine/tenofovir/efavirenz (AtriplaTM). Forty (89%) of the 45 participants were on 
ART at the beginning of the trial while 36 (90%) participants on ART were on a regimen 
containing at least one nucleoside reverse transcriptase inhibitor agent. Twenty-one 
(53%) of the participants on ART were on a regimen containing at least one protease 
inhibitor agent. Eighteen (45%) of the participants on ART were on a regimen containing 
at least one non-nucleoside reverse transcriptase inhibitor agent. One participant (3%) 
was using an ART containing an integrase inhibitor, but none of the participants on ART 
were on a regimen containing entry inhibitors. Undetectable HIV viral load levels (less 
than 48 copies/ml) were noted in 31/45 (69%) of participants. The average CD4 cell 
count was 518 cells/ mm3 for all participants, while the median nadir CD4 was 215 
cells/mm3. The participants used a combination of nonsteroidal anti-inflammatory drugs 
(NSAID), antidepressants, calcium channel α2-δ ligands and opioid analogs as primary 
agents to manage DSPN pain. In addition, other agents such as anti-convulsants and 
muscle relaxants were included alongside the other systemic agents to maximize pain 
relief. The most common analgesic agents used by this sample of participants was 
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antidepressants (22/45 participants) and calcium channel α2-δ ligands (28/45 
participants). The participants’ characteristics at baseline are reported in Table 4.1. The 
groups were equivalent for all baseline demographics and pharmacological regimens. The 
following participant’s characteristics approached statistical significance difference 
between the intervention groups at baseline: age of participants, exposure to neurotoxic 
ART regimen, and baseline CD4 cell counts. The participants in the splint group 
appeared to be older, had prior exposure to neurotoxic ART regimens, and had higher 
baseline CD4 cell counts than those randomized to the liner group. 
Sixteen (70%) of the 23 participants in the splint group reported discomfort with 
immobilization while using the splints during the first two weeks of the trial, however 
these issues resolved by week three of the trial. No comfort-related issues were reported 
by any of the participants in the liner group. Thirty-three (73%) of the 45 participants 
reported painful night calf cramps at the beginning of the study. Painful night cramps 
were reported in 17 (74%) participants in the splint group and 16 (73%) in the liner group 
at baseline assessment. Fourteen (82%) of 17 participants in the splint group originally 
reporting night cramps returned for the final follow-up session; none of them reported 
painful cramps at the end of the study. Night calf cramps continued to be reported at the 
end of the trial in 14 (88%) of the 16 participants in the liner group that originally 
reported night cramps at baseline.  
For the dependent variable pain, the splint group’s mean percentage pain score 
reduced 11.89±23.23% from baseline to week three, and 32.89±23.23% from baseline to 
week six. The average percentage pain reduction in the liner group was 10.12±22.12% 
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from baseline to week three, and 14.52±39.74% from baseline to week six. The median 
pain reduction from baseline to week six was 34% and 8% in the splint and liner groups, 
respectively. Eleven (61%) of the 18 participants in the splint group and 5/19 (26%) in 
the liner group reported at least 30% pain reduction from baseline at week six of this trial. 
The average percentage pain reduction in the intervention groups at the respective follow-
up intervals is depicted in Figure4.2. 
The sleep scores improved from baseline to week six in both groups. Refer to 
Table 4.2 for detailed means. The change in sleep and pain scores at each follow-up 
interval is depicted in Figure 4.3 and Figure 4.4, respectively, with sleep scores 
normalized to 100. Five (11%) of the 45 participants were using sedative-hypnotic agents 
(zolpidem or AmbienTM) to assist in optimizing sleep. Two (4%) of the five participants 
were randomized to the splint group while the other three (7%) participants were 
assigned to the liner group. The average sleep score for these participants at baseline was 
similar to the rest of the participants in the study (14.40±3.58).  
Pain Scores (Intention-To-Treat Analysis) 
A repeated measures ANOVA was conducted to test the null hypothesis that there 
is no difference in pain scores between the intervention groups. To address the potential 
for missing data to affect the results, the analyses were repeated with the imputed data 
using the aforementioned approach to handle missing data. For the dependent variable 
pain, Mauchly’s test for sphericity demonstrated that the assumption of sphericity was 
not tenable for the factor pain scores, χ2(2) =15.47, p<0.0005;, therefore, degrees of 
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freedom were corrected using Huynh-Feldt estimates of sphericity (ε = 0.81). The 
repeated measures ANOVA was found to be significant, F(1.61,69.26)=15.38, p<0.0005. 
No significant interaction was found between the factors time and intervention group, 
F(1.61, 69.26)=0.781, p=0.44. The main effect of time for the factor pain score was 
found to be significant, F(1,43)= 19.77,η2=0.32, p<0.0005. No significance main effect 
was found for the intervention group assignment on pain scores, F(1,43)=0.01, p=0.935. 
The observed statistical power for the between-group analysis was 0.05, and 0.97 for the 
within-group analysis.  
Per protocol analysis. Mauchly’s test for sphericity demonstrated that the 
assumption of sphericity was not tenable for the factor pain scores, χ2(2) = 9.46, p 
=0.009, therefore degrees of freedom were corrected using Huynh-Feldt estimates of 
sphericity (ε = 0.86). The repeated measures ANOVA for the dependent variable pain, 
was found to be significant, F(1.71,56.46)=14.07, p<0.0005. No significant interaction 
was found between the factors time and intervention group for pain score, F(1.71, 
56.46)=1.28, p=0.282. The lack of significant interaction between the interventions 
suggests the lack of independence between the interventions over time. The main effect 
of time for the factor pain score was found to be significant, F(1,33)= 9.01, η2=0.36, 
p=0.001. This indicates that there was a significant decrease in pain scores from baseline 
to week three, baseline to week six, and from week three to week six regardless of group 
assignment. No significance main effect was found for group assignment on pain scores, 
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F(1,33)= 1.83, p=0.185. The observed statistical power for the between-group analysis 
was 0.26 and 0.99 for the within-group analysis.  
Therefore, for the dependent variable pain, only small reductions in statistical 
power and effect size were found to be different between the intention-to-treat analysis 
and the analysis conducted on the data retained. No overall changes in statistical 
significance were noted. 
Sleep Scores (Intention-To-Treat Analysis)  
The same data extrapolation described for pain scores was used to impute the 
missing sleep scores. A Kruskal-Wallis ANOVA failed to reveal a significant between-
group effect of group on sleep scores at week three (χ2(2) =0.797, p=0.372) and week six 
(χ2(2) = 0.002, p=0.962) of this trial. A Friedman ANOVA revealed a significant effect 
over time on sleep scores, regardless of group assignment, χ2(2) =16.66, p<0.0005.  
Per protocol analysis. A Kruskal-Wallis ANOVA was conducted to test the null 
hypothesis that there is no difference in sleep scores between the intervention groups. The 
Kruskal-Wallis ANOVA failed to reveal a significant effect between the groups on sleep 
scores at week three (χ2(2) =1.628, p=0.202), and at week six (χ2(2) = 0.109, p=0.741) of 
this trial. A Friedman ANOVA revealed a significant reduction in sleep scores over time, 
which was independent of intervention group assignment, χ2(2) =12.32, p=0.002. No 
significant differences were found between the intention-to-treat analysis and the data 
retained for final analysis for sleep scores. 
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Contrasts of Interest 
Independent student-t test were performed to test the null hypothesis that there is 
no difference in pain scores among the intervention groups at week three and six of this 
trial. No statistically significant difference was found for the contrast of interest at week 
three (t(35)=-1.45, p=0.155, two-tailed) or at week six (t(35)=-0.61, p=0.544, two-tailed). 
The contrast of interest to evaluate the difference in pain scores for participants in the 
splint group from baseline to week six of the trial was evaluated using a paired student-t 
test. The results of the paired student-t test showed a statistically significant reduction in 
pain scores from baseline to week six of this trial, t(17)=4.65, p<0.0005, two-tailed.  
A Mann-Whitney U test was used to analyze the sleep quality index scores to test 
the null hypothesis that the sleep scores are not different between the intervention groups. 
No significant difference in sleep quality index scores was found between the 
intervention groups at week three (p=0.387, r=0.49) or at week six (p=0.126, r=0.54). 
DISCUSSION 
The results of this trial support the hypothesis that the use of night time LE splints 
reduces DSPN-related pain in PLWHA. The median percentage pain score reduction was 
greater than 30% in the splint group compared to less than 10% in the liner group at the 
end of the study. A moderate magnitude effect size on pain was attributed to the use of 
the LE splints in this trial. Additionally, none of the participants randomized to the splint 
group completing this trial reported painful night cramps at the end of this trial. No 
significant differences were found between the splint and liner groups on pain and sleep 
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scores at each respective follow-up interval. The latter contrasts were statistically 
underpowered in this trial. 
 Splinting devices have been used at the wrist to manage symptoms associated 
with carpal tunnel syndrome (CTS). DSPN in PLWHA as well as people living with CTS 
share a similar clinical presentation that includes complaints of hypernociception, 
paresthesia and allodynia. In a recent Cochrane database review, O’Connor et al.18 
selected 21 trials involving 884 people to explore the efficacy of non-pharmacological 
treatments used in the management of CTS. The authors concluded that the use of a wrist 
brace, at night or continuously, improved symptoms of pain in people living with CTS. 
Many of the currently approved pharmacological agents to manage neuropathic pain have 
been approved for use with less than half of the participants reporting greater than 30% 
pain relief, while none have proven superior to placebo application in HIV-related 
DSPN.7,9,19 The neuropathic pain management guidelines from the International 
Association for the Study of Pain (IASP) suggests that a 30% pain reduction from 
baseline represents an effective analgesic treatment outcome.7 A night time splinting 
program appears to meet the established guidelines for effective pain management in 
HIV-related DSPN. The splinting program provides a non-pharmacological, cost-
effective, patient-modulated option to manage disrupting neuropathic symptoms in this 
patient cohort. The findings of the current study are congruent with those reported in a 
pilot study on the use of LE splints to manage pain in PLWHA and DSPN.13 The authors 
reported a 20% reduction in pain and sleep scores reduction following a three-week night 
time use of LE splints. A moderate effect size was attributed to the splints for pain and 
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sleep scores during that LE splints trial.  
The analgesic effect and lack of painful night cramps in this trial may be 
attributed to the splints’ short-term immobilization effect. Huber et al.20 investigated the 
inhibitory effect of 12-hour immobilization of the hand on motor task coordination, 
somatosensory evoked potentials (SEP), motor evoked potentials (MEP) and sleep slow 
wave activity. A brief reaching task performed in the morning with the left hand was used 
to assess motor coordination. The left arm of the participants was immobilized for 12 
hours using an arm sling with a bandage covering the left hand and wrist. A significant 
correlation was found between SEP and ability to perform the motor task on the 
immobilized arm when comparing the kinematic observations and EEG activity. The SEP 
activity in the contralateral sensory motor cortex showed an increased latency and 
decreased amplitude following median nerve stimulation of the immobilized extremity. 
The MEP exhibited a 30-50% decrease in the peak-to-peak amplitude in the immobilized 
group when comparing the pre and post immobilization recordings, p<0.01. A significant 
contralateral decrease in sleep slow wave activity (SSWA) amplitude was detected 
corresponding topographically to the somatosensory cortex associated with hand control. 
The authors attributed the changes observed in motor coordination, SEP and SSWA to 
inhibitory neuroplastic events resulting from the short-term sensory deprivation and 
immobilization of the upper extremity.  Additionally, animal models suggest the presence 
of an analgesic effect associated with acute and intermittent immobilization.21-24 The 
body of evidence in these animal models suggest that immobilization alters endogenous 
endorphins, serotonin absorption, and acetylcholine activity in the hippocampus resulting 
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in intrinsic pain modulation.24 Seo et al.21 used an inflammatory mouse model to evaluate 
the effect of single and repeated immobilization on the endorphin, serotonin and 
endocannabinoid systems. The immobilization stress was achieved by placing mice in 50 
ml test tubes. The mice were placed in the immobilized posture for one hour daily for 
seven or 14 days in the repeated immobilization model. The inflammatory reaction was 
achieved by injecting the hind leg of the mice with formalin. The authors reported an 
increased expression of hypothalamic propiomelanocortin gene and endorphins following 
immobilization activating the pain modulation pathway.21  
All participants in the current study were classified as poor sleepers based on the 
PSQI scores at baseline and at each follow-up session in the current study. Sleep 
disturbances are commonly reported in chronic pain conditions including those associated 
with chronic neuropathic pain.25-27 Sleep disturbances are frequently reported in PLWHA, 
with more than 50% of these individuals reporting some level of sleep disturbances.14,28-30 
Aouizerat et al.31 quantified the impact of pain on sleep and other symptoms reported by 
PLWHA. The authors enrolled 317 participants, with 175 (55.2%) of these participants 
reporting some degree of pain. The participants completed the General Sleep 
Disturbances Scale (GSDS).  The authors described higher GSDS scores for those 
PLWHA reporting pain than for those not reporting pain, p<0.001. The authors 
concluded that sleep disturbances are both common and coexist with pain in PLWHA.32 
Galer et al.27 surveyed 105 people living with diabetes-related neuropathic pain in a 
descriptive correlation study to evaluate the impact of neuropathic pain on quality of life. 
The authors reported that 57% of the participants reported substantial sleep disruptions 
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directly attributed to neuropathic pain symptoms. Additionally, 52% of the participants in 
Galer’s study reported worsening of neuropathic pain symptoms at night. 
The participants in the current study exhibited 17% more sleep disturbances, at 
baseline, than people living with insomnia.17 The PSQI scores decreased by the end of the 
trial in both treatment intervention groups to levels similar to that observed in people 
living with insomnia.17 It is interesting to point out that only a small number of 
participants were using zolpidem (AmbienTM) to optimize sleep, and that the sleep quality 
index scores in these individuals were similar to the rest of the participants. These 
findings support the presence of an association between the constructs of sleep and pain. 
The pain-sleep association has been reported as both a linear and circular relationship 
between these variables in people living with neuromuscular pain syndromes.26,33 The 
linear model suggest a direct association between pain and sleep, where pain directly 
interferes with sleep. In this model, addressing the source of the pain directly improves 
sleep quality. The circular model postulates a summative and circular effect, where 
chronic pain contributes to poor sleep; while a state of chronic sleep deprivation 
potentiates pain integration.26 Either model supports the net beneficial effect of effective 
pain management on sleep quantity and quality.  
The current study was limited by its inability to confirm the DSPN diagnosis with 
more invasive clinical tests such a punch skin biopsies. Additionally, all of the 
participants were recruited at a public outpatient clinic where the demographic 
characteristics may differ from those PLWHA and DSPN followed in private practice 
settings. PLWHA with recent HIV/AIDS diagnosis may not have been adequately 
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represented. Finally, the primary investigator responsible for data collection and analysis 
was not blinded to the group allocation of the participants for any of the follow-up testing 
sessions. 
SUMMARY 
The use of night time LE splints reduces pain in PLWHA and DSPN. No 
differences were found in pain reduction between the splint application and a similar 
application of the liner of the splint only. Sleep quality scores were improved in both the 
splint and liner only applications from baseline to week six of this trial. Future studies are 
needed to identify and validate effective non-pharmacological interventions targeting 
pain and sleep disruption management in PLWHA and DSPN. Moreover, studies are 
needed to evaluate the clinical relevance to a progressive splinting or immobilization 
intervention. The proposed staging may begin with the liners of the splint only for an 
initial phase to accustom PLWHA and DSPN to using these devices, progressing to using 
the frame of the splint for the remainder of the trial with adequate post-intervention 
follow-up periods. Finally, studies are needed to evaluate the theory that the analgesic 
effect observed may be the result of central neuroplastic events, modulated by 
intermittent limb immobilization. 
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CHAPTER V 
 
REVIEW OF DEPENDENT VARIABLES AND FUTURE AVENUES OF RESEARCH 
INTRODUCTION 
Symptom management associated with distal sensory peripheral neuropathy 
(DSPN) in people living with human immunosuppressive virus (HIV) infection and 
acquired immunodeficiency syndrome (AIDS) poses a significant challenge in clinical 
settings.1 The current study provided additional insight about the realities of people living 
with HIV and AIDS (PLWHA) related DSPN and its impact on function, pain, sleep 
disruptions, as well as the use of splints to mitigate these disruptions. Many research 
questions remain unanswered and are worthy of future queries. The purpose of the 
current chapter is to propose future research avenues in light of the current findings 
concerning the use of lower extremity (LE) splints, function, prevalence of painful night 
cramps in the majority of participants, pain, sleep disturbances, and systemic 
considerations to manage HIV-related DSNP pain. 
SPLINTING 
The nighttime use of LE splints that immobilize the ankle joints in neutral 
position appears to be viable as a non-pharmacological analgesic option in PLWHA and 
DSPN. An analgesic effect was observed in the majority of participants randomized to 
this intervention in the current parallel intervention design research protocol. The effect 
size attributed to the splints appeared to be moderate in magnitude on self-reported pain. 
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Multi-center trials with additional participants are needed to validate the analgesic effect 
attributed to these devices compared to placebo applications without immobilization 
characteristics in crossover trials or parallel intervention groups.  
The majority of participants randomized to the splint group reported discomfort in 
the initial weeks of the trial, whereas no discomfort was reported in the parallel 
intervention using the liner of the splints. Only a small proportion of participants in the 
liner group reported pain reduction greater than 30% from baseline measures. The data 
collected in this trial suggest that future interventional studies using LE splints should 
account for the initial period of discomfort associated with the use of these devices. It is 
conceivable that the splints provide a low load static stretch to the plantar flexor muscle 
group, by intermittently immobilizing the ankle joint in 0 degrees of dorsiflexion. It is 
plausible that small range of motion restrictions in the sagittal plane at the ankle and foot 
may be at least partly responsible for the discomfort reported by the participants 
randomized to the splint group. However, the range of motion at the ankle and foot were 
not quantified in the current intervention trial. The splint liners, which are made of 
compliant foam material, offer minimal structural support to the posterior aspect of the 
lower leg and plantar surface of the foot. The liner is fabricated to conform to the plastic 
frame of the splint. The structural support provided by the liner is minimal, but may not 
have been negligible in some of the individuals randomized to this intervention group. 
The small structural support inherent to the liner may account for the low statistical 
power observed in the statistical comparison to evaluate the analgesic effect between the 
splint and liner groups in the current intervention study. Additionally, the flexible 
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characteristic of the splint liner may also account for the lack of self-reported discomfort 
associated with their use by participants randomized to this intervention. Future studies 
using LE splints in DSPN may evaluate the value of staging the splinting intervention by 
initially using the liners for a two-week acclimation period followed by the introduction 
of the splints’ structural frame for the remainder of the trial. Additionally, the analgesic 
effect associated with unilateral alternated application of the ambidextrous WalkaboutTM 
(Don Joy Orthopedics Vista, CA) splint, used in the current study, compared to 
concurrent bilateral application of the splints may be of interest in clinical settings. The 
unilateral use of ambidextrous splints may aid in improving compliance, decrease 
discomfort issues and reduce the cost of this non-pharmacological intervention. Lastly, it 
is important to note that the supine position at night placed the splinted LE’s 
gastrocnemius muscle in a stretched position for the duration of the application. The 
participants randomized to the splint group may have reported less comfort related issues 
at the beginning, had they been instructed to use a pillow under their knee joint to reduce 
the stretching moment of torque on the gastrocnemius muscle. 
PRESENCE OF NIGHT CRAMPS 
LE cramps are reported in the majority of individuals living with HIV-related 
DSPN1-3 and nighttime exacerbation of pain and sleep disturbances appear to be present 
in other cohorts of non-PLWHA and DSPN.4 Greater than 70% of the participants in the 
current study reported the presence of painful night cramps at baseline assessment. The 
data collected in a case series report from seven PLWHA and DSPN5 suggest significant 
decreases in H-reflex excitability in these individuals. The H-reflex activation threshold 
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in PLWHA and DSPN was reportedly difficult to elicit and had a longer latency than 
non-PLWHA controls using the same apparatus and protocol. A positive association 
between pain reduction and H-reflex amplitude was also reported in this small case study 
series. The findings of this case series suggest an analgesic relationship linking peripheral 
nerves and spinal networks. The small number of participants represented a major 
limiting factor in this report. Therefore, future studies incorporating electromyography 
(EMG) parameters and nerve conduction velocity (NCV) are needed to evaluate the 
integrity of neuronal pathways and their response to analgesic interventions in PLWHA 
and DSPN.  
FUNCTION 
All participants in the current study, regardless of gender, exhibited lower six-
minute walk distance (6MWD) when compared to non-HIV related DSPN cohorts. The 
6MWD is often used as a clinical surrogate of functional endurance, because of its 
association with maximum oxygen consumption capacities.6 The originally planned 
secondary analysis to identify factors exerting significant variance on function in the 
presence of HIV-related DSPN could not be conducted due to unexpected recruitment 
difficulties and relative low participant enrollment. Despite the limitation of a small 
sample size, the correlation analysis revealed a bimodal distribution in the distance 
walked among the participants in the current study. The scatter plot representing 6MWDs 
revealed the presence of a bimodal distribution, when setting a threshold between groups 
at 250 meter (m) walking distances. The group with shorter walking distances included 
74% of all women in the current study, which was corroborated by the significant 
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association between gender and 6MWD. Bautmans et al.7 reported that gender 
differences accounted for 31% of the variability associated with the 6MWD in a cohort of 
156 community dwelling older adults. The difference in the absolute distance walked 
between men and women in Bautman’s study was reported significant at 11%, with men 
walking longer distances. In contrast, the group with shorter walking distances in the 
current study walked on average one-third of the distance walked by the participants in 
the group with longer walking distances. The discrepancy observed in the current cohort 
of PLWHA and DSPN participants provides a valuable insight to consider when working 
with these individuals. Future studies in PLWHA and DSPN cohorts ought to attempt 
recruiting larger number of participants to substantiate these findings. Investigators 
should consider the presence of significant discrepancies in walking distances between 
men and women, while confirming the lack of gender influence in regards to pain, sleep, 
and ability to perform a forward reach task. Additional studies may be warranted to 
ascertain the minimal clinical important difference of the 6MWD in this patient 
population.  
It is theoretically conceivable that the chronic sensory nerve damage associated 
with HIV-related DSPN may also negatively impact the normal functioning of associated 
motor units. The influence on these motor units remains unknown and is worthy of 
further investigation; especially as it relates to one’s ability to efficiently perform 
activities of daily living and function in the community. Quantified measures of strength 
at major muscle groups in the lower extremities should also be included to evaluate their 
ability to contract and generate the necessary torque upon surrounding joints.  
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As a result, the following research questions emerged in regards to functional 
performance in PLWHA and DSPN: does this cohort of individuals exhibit decreased 
cardiovascular endurance as measured by the maximum oxygen volume consumption? 
Does this cohort of individuals exert lower torque outputs at the major muscle groups of 
the LE? Do EMG and NCV parameters in PLWHA and DSPN differ from those observed 
in age-matched cohorts living without HIV infection? Are there significant gender 
differences in cardiovascular endurance or strength in PLWHA and DSPN?  
PAIN AND SLEEP DISTURBANCES 
 All of the participants in the current study reported significant pain and sleep 
disturbances. The baseline pain scores measured by the Neuropathic Pain Scale (NPS) 
indicate a state of moderate to severe discomfort. The overwhelming majority of 
participants were using a combination of analgesic agents to manage their DSPN 
associated pain. The International Association for the Study of Pain (IASP) guidelines for 
the management of neuropathic pain recommend analgesic interventions trials for a 
period of four to 12 weeks, followed by periodic re-assessment of the analgesic 
effectiveness of these interventions.8,9 Close monitoring of all analgesic interventions is 
recommended to evaluate their respective effectiveness in order to optimize pain 
management in these individuals. Certain symptoms associated with DSPN appear 
universal to all neuropathies; these include sensations of “sharp,” “hot,” “dull,” and 
“deep” pain.10  
In addition to its inherent face validity, the NPS was developed to capture the pain 
experience in the presence of neuropathic conditions of multiple etiologies.11 The NPS 
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comprises ten different 0-10 numeric rating scales, which have been reported to exhibit 
higher reliability in measuring pain with low-literacy individuals in osteoarthritic cohorts, 
than the visual analog scale (VAS).12 The pain scores obtained with all scoring variants 
of the NPS exhibited a high degree of association with each other in the current study. As 
a result, any of the scoring methods of the NPS: 1) NPS-8 (“sharp,” “hot,” “dull,” “cold,” 
“sensitive,” “itchy,” “deep” and “surface” pain), 2) NPS-4 (including “sharp,” “hot,” 
“dull” and “deep” pain), 3) NPS-Non allodonyc (including all scales of pain except 
“surface” and “skin sensitivity” pain), and 4) the NPS-10 or global score may also prove 
sensitive to changes in pain following analgesic interventions.  
No significant differences based on gender were found in regards to self-reported 
pain, forward reach, and sleep disturbances in the current study. Self-reported pain and 
sleep disturbances exhibited a significant correlation in the participants in the current 
study. Sleep efficiency, defined as the ratio between the numbers of hours slept divided 
by the number of hours in bed,13 exerted a small influence on the 6MWD, while self-
reported pain failed to exhibit any influence on ambulation distances. The lack of direct 
association between pain and ambulation distances may reflect the multifactorial nature 
of human physical performance. As such, physical performance measures should be 
combined with self-reported measures of function in order to comprehensively appraise 
the impact of pain and sleep disturbances on function. 
SYSTEMIC CONSIDERATIONS 
Pharmacological agents exhibiting positive analgesic reports in other neuropathic 
conditions have failed to prove more efficacious than placebo medications in PLWHA 
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and DSPN.8,9 Many of the studies evaluating the analgesic efficacy of these systemic 
agents in PLWHA utilized pain assessment tools lacking sensitivity and specificity in the 
context of neuropathy-associated conditions, such as the Gracely pain scale or the 
VAS.3,14,15 Conversely, similar studies of these agents in non-HIV cohorts with DSPN 
were able to quantify the respective analgesic effect associated with these 
interventions.16-20 Thus, future studies investigating the analgesic effects of systemic 
agents may enhance the ability to detect treatment effects by including the NPS among 
the pain measures.  
HIV-related DSPN appears to be mediated by HIV Glycoprotein-120 exposure to 
the neuraxis.21 The surface of neurons is likely exposed to chemical irritations mediated 
by the partial binding of Gp-120 to their CCR5 receptors.25,26 In the presence of viremia, 
neurons are exposed to chemokines, leading to damage at spinal interneurons, dorsal root 
ganglia, and distal nerve root endings.21 Many of the studies evaluating the analgesic 
effect of systemic agents did not control for viremia in the study participants.3,22 The 
primary recommendation for the management of neuropathies is to address the 
underlying cause of the neuropathic condition whenever possible.9 Failure to control for 
active viremia could theoretically mask the presence of an analgesic effect associated 
with these pharmaceutical agents. New studies evaluating the analgesic effect of these 
agents to manage DSPN-related pain in HIV cohorts are needed to validate their usage in 
this patient population. These new studies would need to control for parameters that 
introduce inherent variability to analgesic interventions such as a longitudinal measure of 
cumulative HIV viremia. In addition, the overall analgesic effect of combining LE 
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splinting and systemic analgesic agents as part of a comprehensive pain management 
intervention warrants further investigation. 
 New antiretroviral medications targeting CCR5 chemokine receptors23,24 may 
offer prophylactic neuro-protective properties by reducing the chemokine activity. 
Evidence surrounding their anti-inflammatory properties is emerging in other 
inflammatory conditions such as inflammatory bowel syndrome, rheumatoid arthritis, and 
hepatitis C.23 Theoretically, the blocking of the CCR5 chemokine receptors on the surface 
of neurons25,26 may reduce the chemokine activity that causes damage the neuraxis and 
preserve the integrity of central or peripheral neuronal networks. Studies are needed to 
evaluate this theoretical construct in HIV cohorts with active peripheral and perhaps even 
central nervous system pathologies. 
CONCLUSION 
 The purpose of the research enterprise is often portrayed as a quest for answers to 
questions, but often results in germinating new interesting queries surrounding the 
original construct of interest. The work presented in this manuscript is no exception. 
Many questions are worthy of exploration in order to develop a more comprehensive 
understanding of the factors impacting the lives of PLWHA and DSPN, as well as 
developing evidence-based intervention for effective symptom management of HIV-
associated DSPN. Of paramount interest would be to categorically evaluate the analgesic 
effect of LE splints on HIV-related DSPN pain against a placebo intervention to validate 
its utilization in this patient population.  
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CHAPTER VI 
 
CONCLUSION 
 
Distal sensory peripheral neuropathy (DSPN) is reported to increase in prevalence 
as human immunodeficiency virus (HIV) infection progresses into acquired 
immunodeficiency syndrome (AIDS).1 The damage observed in the peripheral nerves can 
be intermittent, episodic, or even progressive over many years and can become disabling 
to the individual.1-3 DSPN in people living with HIV or AIDS (PLWHA) is mediated by 
HIV’s Glycoprotein-120 (Gp-120) exposure to the neuraxis.3 Chronic Gp-120 exposure 
triggers endogenous and exogenous chemokine production damaging neuronal cell 
bodies and axons.3-6 This inflammatory mediated damage leads to neurite damage and 
retraction at the periphery, cell death in the dorsal root ganglia, astrocytosis in the spinal 
cord, and sensitization at the central processing centers.3,4 The persistent state of 
hypernociception leads to inadequate limbic system integration of the peripheral signal 
and altered pain perception.3  Based on the pathophysiological evidence surrounding 
HIV-related DSPN, modern antiretroviral medication may represent a first line treatment 
option to manage DSPN-related pain.  
Neuropathic pain management has been primarily delegated to using systemic 
analgesic agents.7 These pharmacological agents exert an overall inhibitory effect on the 
neuraxis by optimizing γ-aminobutyric acid (GABA) agonist pathways and regulating ion 
channel function at the cellular level.7 Topical agents have proven complementary to 
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systemic analgesics in the management of pain associated with neuropathic conditions.8,9 
The analgesic effect achieved following topical analgesic applications demonstrates the 
presence of important pain generating mechanisms lodged at the periphery.9-11 The 
neuropathic pain management guidelines recommend aiming for 30% pain reduction 
from baseline for an intervention to be considered effective in managing neuropathic 
pain.7 The neuropathic pain treatment guidelines recommend a stepwise introduction of 
systemic analgesics, allowing up to a 12-week trial period to evaluate their respective 
efficacy in managing neuropathic pain.7 To date, none of the currently approved systemic 
analgesics to manage neuropathic pain have proven to be more effective than placebo 
interventions in individuals living with HIV-related DSPN.7-9 Few effective non-
pharmacological interventions to manage neuropathic pain have been reported in the 
literature.12,13  
The use of night time LE splint application may be an effective adjunctive non-
pharmacological intervention to manage neuropathic pain.13  Paralleled evidence 
supporting its use is reported in peripheral neuropathy conditions such as carpal tunnel 
syndrome.14,15 Sleep quality scores and self-reported pain improved in both the splint and 
liner only applications from baseline to week six of the current study. The use of night 
time LE splints was found to significantly reduce pain in PLWHA and DSPN. No 
significant differences were found in pain reduction or improvement in sleep between the 
intervention groups at each of the scheduled follow-up sessions. The participants in the 
current study were on a stable pharmacological regimen to manage pain and HIV 
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replication. At baseline, the majority of participants reported moderate to severe pain and 
lower extremity cramps interfering with normal sleep.  
Pain, sleep and functional disturbances are reported commonly in HIV-related 
DSPN.16,17 Sleep disturbances have been associated with impacting ambulation 
parameters in adults.18,19 Instruments with established psychometric properties regarding 
the measurement of function, pain and sleep quality provide additional understanding of 
the impact of DSPN in PLWHA. A decrease in the overall functional status is also 
reported in PLWHA when compared to age-matched seronegative cohorts.20,21 Functional 
changes, including gait speed22 and gait quality23,24 and overall physical endurance,25 
have been associated with neuropathic conditions further compounding the complexity of 
symptoms reported by PLWHA and DSPN and leading to disability or participation 
restrictions in society.  
The data reported in the current study suggest the presence of significant 
relationships between the constructs of pain, sleep disturbances, and function. Of 
particular interest are the poor sleep scores recorded in PLWHA and DSPN that were 
found to be 17% worse than those reported in people living with a clinical diagnosis of 
insomnia.26 The total distance walked in six minutes in PLWHA and DSPN appears to be 
significantly associated with sleep efficiency and not self-reports of DSPN-associated 
pain. Paradoxically, the results of the reaching task test suggest a normal ability to 
volitionally translate the center of mass along the sagittal plane and exhibited a 
significant association with the distance walked in six minutes. The latter may suggest the 
presence of separate, yet related, constructs of physical endurance and balance.  
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Future researchers should explore and seek to validate the magnitude of gender 
differences in distance walked during the six-minute walk test as reported in the current 
study. Validation studies comparing LE splinting application to placebo interventions are 
needed to ascertain the analgesic effects observed in the current study in mitigating pain 
and sleep disruptions in PLWHA and DSPN. Moreover, studies are needed to evaluate 
the clinical relevance of a progressive splinting or immobilization intervention. The 
proposed staging might begin with only using the splint liners to accustom PLWHA and 
DSPN to these devices, progressing to using the frame of the splint for the remainder of 
the trial with adequate post-intervention follow-up periods. Finally, studies are needed to 
evaluate the theory that the analgesic effect observed might be the result of central 
neuroplastic events modulated by intermittent limb immobilization. 
HIV-related DSPN exhibits an amalgam of confounding clinical symptoms 
forcing PLWHA and DSPN to peregrinate among a spectrum of healthcare providers 
seeking relief. Factors of compliance, complex antiretroviral regimens, polypharmacy, 
and issues of analgesic medication dependence further complicate the management of 
symptoms in these individuals. The level of clinical complexity should challenge 
clinicians to select appropriate evidence supported interventions as well as to seek to 
validate novel management options. 
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APPENDIX B 
 
WalkaboutTM Splint (Don Joy Orthopedics, Vista, CA) 
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WalkaboutTM Splint with liner (Don Joy Orthopedics, Vista, CA) 
 
 
WalkaboutTM Splint with liner removed (Don Joy Orthopedics, Vista, CA) 
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APPENDIX C 
 
Neuropathic Pain Scale (Galer and Jensen 1997)  
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APPENDIX D 
 
Pittsburgh Sleep Quality Index (Buysse et al. 1987) 
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Table 3.1 Participants Characteristics   
(n=45) Mean (SD) 
Age (years) 48.42 (8.13) 
Ethnicity   
  African American 24/45(53%) 
  White 15/45(33%) 
  Latino 5/45(11%) 
  Other 1/45(2%) 
Gender   
  Women 19/45(42%) 
  Men 26/45(58%) 
CD4 (Cell count/mm3) 517.67 (241.07) 
Nadir CD4 (Cell count/mm3) 215 
HIV Viral Load (log10) 2.10 (0.93) 
Undetectable Viral load (<48 copies/ml) 31/45 (69%) 
Years since original HIV/AIDS diagnosis 10.82 (6.79) 
Pain Scores (0-100)   
  NPS-10 60.77 (17.85) 
  NPS4* 61.33 (20.10) 
  NPS8* 57.03 (18.71) 
  NPS-NA* 62.51 (17.25) 
  NPS-Intensity* 73.33 (22.66) 
Sleep Scores   
  PSQI 14.62 (4.28) 
  PSQI-Quality 2.16 (0.85) 
  PSQI-Latency 2.33 (0.83) 
  PSQI-Duration 1.87 (1.20) 
  PSQI-Efficiency 1.78 (1.36) 
  PSQI-Disturbances 2.49 (0.63) 
  PSQI-Medications 1.91 (1.29) 
  PSQI-Daytime Dysfunction 2.09 (0.90) 
Function   
  6MWD (m) 243.99 (141.04) 
  Forward Reach (cm)** 36.07 (7.37) 
*normalized to 100 
** Average of three consecutive trials, n=44   
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Figure 3.1 Average Pittsburgh Sleep Quality Index (PSQI) Subscale Scores 
(maximum score=3) 	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Figure 3.2 Neuropathic Pain Scale Scoring Options and NPS-Pain Intensity 	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Figure 3.3 Function Data Point Distribution 	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Assessed for eligibility 
(n=110) 
Excluded  (n= 66) 
♦	  	  	  Not meeting inclusion criteria 
(n=54) 
♦	  	  	  Declined to participate (n= 12) 
♦	  	  	  Other reasons (n= 0) 
Intention-to-treat analysis (n=23) 
Per protocol analysis (n=16)  
Contrasts of interest (n=18) 	  
Lost to follow-up, could not be 
reached by telephone, did not return 
for scheduled follow-ups (n=2) 
Discontinued intervention for 
personal reasons (n=3) 
Missed one follow-up session (n=2) 
Allocated to intervention (n=23) 
♦	  Received allocated intervention 
(n=23)	  
♦	  Did not receive allocated 
intervention (n=0)	  
Lost to follow-ups (n=1) 
Missed one follow-up session (n=1) 
Allocated to Liners group (n=23) 
♦	  Received allocated intervention 
(n=22)	  
♦	  Did not receive allocated 
intervention, because of recent 
type-II diabetes (n=1)	  
Intention-to-treat analysis (n=22) 
Per protocol analysis (n=19) 
Contrasts of interest (n=19)	  	  
Randomized (n=46) 
Figure 4.1 Participant Flow Diagram 
	   174	  
	  
 
Figure 4.2 Percentage Pain Reduction 
*significant change (contrast of interest) in percentage pain reduction in the splint group 
from baseline to week six, p<0.0005. 
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Figure 4.3 Pain Scores 
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Figure 4.4 Sleep Scores (Normalized to 100) 
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